WO2008147283A1 - The use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants - Google Patents
The use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants Download PDFInfo
- Publication number
- WO2008147283A1 WO2008147283A1 PCT/SE2008/000352 SE2008000352W WO2008147283A1 WO 2008147283 A1 WO2008147283 A1 WO 2008147283A1 SE 2008000352 W SE2008000352 W SE 2008000352W WO 2008147283 A1 WO2008147283 A1 WO 2008147283A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- autoimmune
- syndrome
- disease
- medicament
- zebularine
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 50
- 208000023275 Autoimmune disease Diseases 0.000 title claims description 17
- 239000003814 drug Substances 0.000 claims abstract description 73
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 10
- 241000124008 Mammalia Species 0.000 claims abstract description 6
- RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 claims description 75
- 210000004027 cell Anatomy 0.000 claims description 43
- 150000001875 compounds Chemical class 0.000 claims description 40
- 239000004480 active ingredient Substances 0.000 claims description 32
- 230000001363 autoimmune Effects 0.000 claims description 27
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 238000002054 transplantation Methods 0.000 claims description 15
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical class C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 14
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 210000001519 tissue Anatomy 0.000 claims description 14
- 210000000056 organ Anatomy 0.000 claims description 13
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 12
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- 210000004698 lymphocyte Anatomy 0.000 claims description 12
- 229960004799 tryptophan Drugs 0.000 claims description 12
- -1 Fonnylanthranilate Chemical compound 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000011580 syndromic disease Diseases 0.000 claims description 11
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 201000006417 multiple sclerosis Diseases 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000003085 diluting agent Substances 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 claims description 8
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims description 8
- 229960002930 sirolimus Drugs 0.000 claims description 8
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 8
- 102000016680 Dioxygenases Human genes 0.000 claims description 7
- 108010028143 Dioxygenases Proteins 0.000 claims description 7
- 102000004877 Insulin Human genes 0.000 claims description 7
- 108090001061 Insulin Proteins 0.000 claims description 7
- 229940125396 insulin Drugs 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- YGPSJZOEDVAXAB-UHFFFAOYSA-N (R)-Kynurenine Natural products OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 claims description 6
- WJXSWCUQABXPFS-UHFFFAOYSA-N 3-hydroxyanthranilic acid Chemical compound NC1=C(O)C=CC=C1C(O)=O WJXSWCUQABXPFS-UHFFFAOYSA-N 0.000 claims description 6
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims description 6
- 208000011231 Crohn disease Diseases 0.000 claims description 6
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 6
- 206010022489 Insulin Resistance Diseases 0.000 claims description 6
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims description 6
- NCIKQJBVUNUXLW-UHFFFAOYSA-N N-methyltryptamine Chemical compound C1=CC=C2C(CCNC)=CNC2=C1 NCIKQJBVUNUXLW-UHFFFAOYSA-N 0.000 claims description 6
- 201000011152 Pemphigus Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 230000001419 dependent effect Effects 0.000 claims description 6
- 230000000779 depleting effect Effects 0.000 claims description 6
- 108020001507 fusion proteins Proteins 0.000 claims description 6
- 102000037865 fusion proteins Human genes 0.000 claims description 6
- HCZHHEIFKROPDY-UHFFFAOYSA-N kynurenic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC(=O)C2=C1 HCZHHEIFKROPDY-UHFFFAOYSA-N 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 claims description 6
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 6
- 108091023020 Aldehyde Oxidase Proteins 0.000 claims description 5
- 102000048262 Aldehyde oxidases Human genes 0.000 claims description 5
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 claims description 5
- 229940045145 uridine Drugs 0.000 claims description 5
- VCKPUUFAIGNJHC-LURJTMIESA-N 3-hydroxy-L-kynurenine Chemical compound NC1=C(O)C=CC=C1C(=O)C[C@H]([NH3+])C([O-])=O VCKPUUFAIGNJHC-LURJTMIESA-N 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 208000001204 Hashimoto Disease Diseases 0.000 claims description 4
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 4
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 4
- 229960003987 melatonin Drugs 0.000 claims description 4
- 229960000485 methotrexate Drugs 0.000 claims description 4
- 229940076279 serotonin Drugs 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- OBFAPCIUSYHFIE-UHFFFAOYSA-N (5-hydroxyindol-3-yl)acetaldehyde Chemical compound OC1=CC=C2NC=C(CC=O)C2=C1 OBFAPCIUSYHFIE-UHFFFAOYSA-N 0.000 claims description 3
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims description 3
- OQUXVPJVBSENGK-QXMHVHEDSA-N (z)-2,5-dicyano-3-hydroxy-n-[4-(trifluoromethyl)phenyl]pent-2-enamide Chemical compound N#CCCC(/O)=C(\C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 OQUXVPJVBSENGK-QXMHVHEDSA-N 0.000 claims description 3
- BISROEGZKWHITE-WCTZXXKLSA-N 1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-fluoropyrimidin-2-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC(F)=C1 BISROEGZKWHITE-WCTZXXKLSA-N 0.000 claims description 3
- ZNHHCVLXECPBLK-DJLDLDEBSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidin-2-one Chemical compound C1=C(C)C=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 ZNHHCVLXECPBLK-DJLDLDEBSA-N 0.000 claims description 3
- BFPYWIDHMRZLRN-UHFFFAOYSA-N 17alpha-ethynyl estradiol Natural products OC1=CC=C2C3CCC(C)(C(CC4)(O)C#C)C4C3CCC2=C1 BFPYWIDHMRZLRN-UHFFFAOYSA-N 0.000 claims description 3
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 3
- QCGTZPZKJPTAEP-NWJCXACMSA-N 2-Aminomuconate semialdehyde Natural products O=C(O)/C(/N)=C/C=C\C=O QCGTZPZKJPTAEP-NWJCXACMSA-N 0.000 claims description 3
- ZGQVEYFFYPOUKD-UHFFFAOYSA-N 2-Formaminobenzoylacetate Chemical compound OC(=O)CC(=O)C1=CC=CC=C1NC=O ZGQVEYFFYPOUKD-UHFFFAOYSA-N 0.000 claims description 3
- QCGTZPZKJPTAEP-REDYYMJGSA-N 2-aminomuconic 6-semialdehyde Chemical compound OC(=O)C(/N)=C\C=C/C=O QCGTZPZKJPTAEP-REDYYMJGSA-N 0.000 claims description 3
- VPIXQGUBUKFLRF-UHFFFAOYSA-N 3-(2-chloro-5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N-methyl-1-propanamine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCNC)C2=CC=CC=C21 VPIXQGUBUKFLRF-UHFFFAOYSA-N 0.000 claims description 3
- YCJNYHCCOXVYAF-UHFFFAOYSA-N 4-(2-amino-3-hydroxyphenyl)-2,4-dioxobutanoic acid Chemical compound NC1=C(O)C=CC=C1C(=O)CC(=O)C(O)=O YCJNYHCCOXVYAF-UHFFFAOYSA-N 0.000 claims description 3
- DUUGKQCEGZLZNO-UHFFFAOYSA-M 5-Hydroxyindoleacetate Chemical compound OC1=CC=C2NC=C(CC([O-])=O)C2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-M 0.000 claims description 3
- ZAYHVCMSTBRABG-UHFFFAOYSA-N 5-Methylcytidine Natural products O=C1N=C(N)C(C)=CN1C1C(O)C(O)C(CO)O1 ZAYHVCMSTBRABG-UHFFFAOYSA-N 0.000 claims description 3
- LFUCRBSGQMAKCO-UHFFFAOYSA-N 5-hydroxyindoleacetylglycine Chemical compound C1=C(O)C=C2C(CC(=O)NCC(=O)O)=CNC2=C1 LFUCRBSGQMAKCO-UHFFFAOYSA-N 0.000 claims description 3
- ZAYHVCMSTBRABG-JXOAFFINSA-N 5-methylcytidine Chemical compound O=C1N=C(N)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 ZAYHVCMSTBRABG-JXOAFFINSA-N 0.000 claims description 3
- ACWKSOUZTQSPNU-UHFFFAOYSA-N 5-methylpyrimidin-2-one Chemical compound CC1=C=NC(=O)N=C1 ACWKSOUZTQSPNU-UHFFFAOYSA-N 0.000 claims description 3
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 3
- 208000002310 Achlorhydria Diseases 0.000 claims description 3
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims description 3
- 206010066728 Acute interstitial pneumonitis Diseases 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 3
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 3
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims description 3
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims description 3
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 3
- OVCDSSHSILBFBN-UHFFFAOYSA-N Amodiaquine Chemical compound C1=C(O)C(CN(CC)CC)=CC(NC=2C3=CC=C(Cl)C=C3N=CC=2)=C1 OVCDSSHSILBFBN-UHFFFAOYSA-N 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 3
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 3
- 206010003645 Atopy Diseases 0.000 claims description 3
- 208000004300 Atrophic Gastritis Diseases 0.000 claims description 3
- 208000002017 Autoimmune Hypophysitis Diseases 0.000 claims description 3
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 3
- 206010064539 Autoimmune myocarditis Diseases 0.000 claims description 3
- 208000031212 Autoimmune polyendocrinopathy Diseases 0.000 claims description 3
- 102100036465 Autoimmune regulator Human genes 0.000 claims description 3
- 208000023328 Basedow disease Diseases 0.000 claims description 3
- 208000027496 Behcet disease Diseases 0.000 claims description 3
- 208000009137 Behcet syndrome Diseases 0.000 claims description 3
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 3
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 3
- 208000024699 Chagas disease Diseases 0.000 claims description 3
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 claims description 3
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims description 3
- FSBKJYLVDRVPTK-UHFFFAOYSA-N Cinnavalininate Chemical compound C1=CC=C2OC3=CC(=O)C(N)=C(C(O)=O)C3=NC2=C1C(O)=O FSBKJYLVDRVPTK-UHFFFAOYSA-N 0.000 claims description 3
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 3
- 208000015943 Coeliac disease Diseases 0.000 claims description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 3
- 206010011878 Deafness Diseases 0.000 claims description 3
- 206010012289 Dementia Diseases 0.000 claims description 3
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 3
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 3
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 108010008165 Etanercept Proteins 0.000 claims description 3
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 claims description 3
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 3
- 208000028387 Felty syndrome Diseases 0.000 claims description 3
- 208000036495 Gastritis atrophic Diseases 0.000 claims description 3
- 208000007465 Giant cell arteritis Diseases 0.000 claims description 3
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims description 3
- 102100033945 Glycine receptor subunit alpha-1 Human genes 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 3
- 208000031071 Hamman-Rich Syndrome Diseases 0.000 claims description 3
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 3
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 3
- 101000928549 Homo sapiens Autoimmune regulator Proteins 0.000 claims description 3
- 101000996297 Homo sapiens Glycine receptor subunit alpha-1 Proteins 0.000 claims description 3
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 3
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 claims description 3
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 claims description 3
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 claims description 3
- 208000011200 Kawasaki disease Diseases 0.000 claims description 3
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 claims description 3
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims description 3
- 208000007820 Lichen Sclerosus et Atrophicus Diseases 0.000 claims description 3
- 206010024434 Lichen sclerosus Diseases 0.000 claims description 3
- 208000005777 Lupus Nephritis Diseases 0.000 claims description 3
- 206010067737 Lupus hepatitis Diseases 0.000 claims description 3
- 206010025327 Lymphopenia Diseases 0.000 claims description 3
- 208000027530 Meniere disease Diseases 0.000 claims description 3
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 3
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 3
- HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 claims description 3
- 208000024599 Mooren ulcer Diseases 0.000 claims description 3
- 206010028424 Myasthenic syndrome Diseases 0.000 claims description 3
- 206010028527 Myelitis transverse Diseases 0.000 claims description 3
- 208000009525 Myocarditis Diseases 0.000 claims description 3
- MVAWJSIDNICKHF-UHFFFAOYSA-N N-acetylserotonin Chemical compound C1=C(O)C=C2C(CCNC(=O)C)=CNC2=C1 MVAWJSIDNICKHF-UHFFFAOYSA-N 0.000 claims description 3
- BYHJHXPTQMMKCA-QMMMGPOBSA-N N-formyl-L-kynurenine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC(=O)C1=CC=CC=C1NC=O BYHJHXPTQMMKCA-QMMMGPOBSA-N 0.000 claims description 3
- 206010029240 Neuritis Diseases 0.000 claims description 3
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 claims description 3
- 206010033645 Pancreatitis Diseases 0.000 claims description 3
- 206010034277 Pemphigoid Diseases 0.000 claims description 3
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims description 3
- 206010065159 Polychondritis Diseases 0.000 claims description 3
- 208000025237 Polyendocrinopathy Diseases 0.000 claims description 3
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims description 3
- 229920000388 Polyphosphate Polymers 0.000 claims description 3
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims description 3
- 208000033464 Reiter syndrome Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 206010072148 Stiff-Person syndrome Diseases 0.000 claims description 3
- 208000036384 Still disease adult onset Diseases 0.000 claims description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 3
- 208000001106 Takayasu Arteritis Diseases 0.000 claims description 3
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 3
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 3
- 241000223109 Trypanosoma cruzi Species 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 206010064996 Ulcerative keratitis Diseases 0.000 claims description 3
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims description 3
- 206010047642 Vitiligo Diseases 0.000 claims description 3
- 208000025749 Vogt-Koyanagi-Harada disease Diseases 0.000 claims description 3
- 229960003697 abatacept Drugs 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 201000004073 acute interstitial pneumonia Diseases 0.000 claims description 3
- 229960002964 adalimumab Drugs 0.000 claims description 3
- 229960000548 alemtuzumab Drugs 0.000 claims description 3
- 208000004631 alopecia areata Diseases 0.000 claims description 3
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 3
- 229960000836 amitriptyline Drugs 0.000 claims description 3
- 229960001444 amodiaquine Drugs 0.000 claims description 3
- 229960004238 anakinra Drugs 0.000 claims description 3
- 208000007502 anemia Diseases 0.000 claims description 3
- 230000000340 anti-metabolite Effects 0.000 claims description 3
- 229940100197 antimetabolite Drugs 0.000 claims description 3
- 239000002256 antimetabolite Substances 0.000 claims description 3
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 3
- 208000020176 autoimmune hypoparathyroidism Diseases 0.000 claims description 3
- 208000006424 autoimmune oophoritis Diseases 0.000 claims description 3
- 201000009771 autoimmune polyendocrine syndrome type 1 Diseases 0.000 claims description 3
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 3
- 229960002170 azathioprine Drugs 0.000 claims description 3
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 3
- 229960004669 basiliximab Drugs 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims description 3
- 229960001076 chlorpromazine Drugs 0.000 claims description 3
- 208000003167 cholangitis Diseases 0.000 claims description 3
- 208000016644 chronic atrophic gastritis Diseases 0.000 claims description 3
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 claims description 3
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 3
- KACPVQQHDVBVFC-OIFXTYEKSA-N cis,cis-2-amino-3-(3-oxoprop-1-enyl)but-2-enedioic acid Chemical compound OC(=O)C(/N)=C(/C(O)=O)\C=C/C=O KACPVQQHDVBVFC-OIFXTYEKSA-N 0.000 claims description 3
- 229960004606 clomipramine Drugs 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 201000003278 cryoglobulinemia Diseases 0.000 claims description 3
- 208000004921 cutaneous lupus erythematosus Diseases 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 108010057085 cytokine receptors Proteins 0.000 claims description 3
- 102000003675 cytokine receptors Human genes 0.000 claims description 3
- 229960002806 daclizumab Drugs 0.000 claims description 3
- 201000001981 dermatomyositis Diseases 0.000 claims description 3
- 201000002491 encephalomyelitis Diseases 0.000 claims description 3
- 206010014801 endophthalmitis Diseases 0.000 claims description 3
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims description 3
- 229930182833 estradiol Natural products 0.000 claims description 3
- 229960005309 estradiol Drugs 0.000 claims description 3
- 229960000403 etanercept Drugs 0.000 claims description 3
- 229960002568 ethinylestradiol Drugs 0.000 claims description 3
- 229960005167 everolimus Drugs 0.000 claims description 3
- 229960003580 felodipine Drugs 0.000 claims description 3
- 229960000556 fingolimod Drugs 0.000 claims description 3
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical compound CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims description 3
- 230000010370 hearing loss Effects 0.000 claims description 3
- 231100000888 hearing loss Toxicity 0.000 claims description 3
- 208000016354 hearing loss disease Diseases 0.000 claims description 3
- 230000002008 hemorrhagic effect Effects 0.000 claims description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims description 3
- 239000003018 immunosuppressive agent Substances 0.000 claims description 3
- 229940125721 immunosuppressive agent Drugs 0.000 claims description 3
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims description 3
- 229960000598 infliximab Drugs 0.000 claims description 3
- 229960000681 leflunomide Drugs 0.000 claims description 3
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 3
- 229950007278 lenercept Drugs 0.000 claims description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 claims description 3
- 229960003088 loratadine Drugs 0.000 claims description 3
- 231100001023 lymphopenia Toxicity 0.000 claims description 3
- 230000001589 lymphoproliferative effect Effects 0.000 claims description 3
- 229950000844 mizoribine Drugs 0.000 claims description 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 3
- 229960003816 muromonab-cd3 Drugs 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 229960004866 mycophenolate mofetil Drugs 0.000 claims description 3
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 3
- MTUIFOCORDEJRB-UHFFFAOYSA-N n-methylserotonin Chemical compound C1=CC(O)=C[C]2C(CCNC)=CN=C21 MTUIFOCORDEJRB-UHFFFAOYSA-N 0.000 claims description 3
- 201000003631 narcolepsy Diseases 0.000 claims description 3
- 229960005027 natalizumab Drugs 0.000 claims description 3
- 208000008795 neuromyelitis optica Diseases 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- ASUSBMNYRHGZIG-UHFFFAOYSA-N omega-N-Methylserotonin Natural products C1=C(O)C=C2C(CCNC)=CNC2=C1 ASUSBMNYRHGZIG-UHFFFAOYSA-N 0.000 claims description 3
- 201000005737 orchitis Diseases 0.000 claims description 3
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 230000000505 pernicious effect Effects 0.000 claims description 3
- 229960000762 perphenazine Drugs 0.000 claims description 3
- 208000015385 phacoanaphylactic uveitis Diseases 0.000 claims description 3
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 3
- 208000000813 polyradiculoneuropathy Diseases 0.000 claims description 3
- 208000011610 primary hypophysitis Diseases 0.000 claims description 3
- 229960003910 promethazine Drugs 0.000 claims description 3
- XFALURCRIGINGT-UHFFFAOYSA-N quinoline-4,6-diol Chemical compound N1=CC=C(O)C2=CC(O)=CC=C21 XFALURCRIGINGT-UHFFFAOYSA-N 0.000 claims description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 3
- 229960004622 raloxifene Drugs 0.000 claims description 3
- 208000002574 reactive arthritis Diseases 0.000 claims description 3
- 201000003068 rheumatic fever Diseases 0.000 claims description 3
- 229960004641 rituximab Drugs 0.000 claims description 3
- 201000000306 sarcoidosis Diseases 0.000 claims description 3
- 230000002889 sympathetic effect Effects 0.000 claims description 3
- 238000003786 synthesis reaction Methods 0.000 claims description 3
- 229960001967 tacrolimus Drugs 0.000 claims description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 3
- 206010043207 temporal arteritis Diseases 0.000 claims description 3
- 229960002784 thioridazine Drugs 0.000 claims description 3
- 208000005057 thyrotoxicosis Diseases 0.000 claims description 3
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims description 3
- 229960002324 trifluoperazine Drugs 0.000 claims description 3
- 239000001226 triphosphate Substances 0.000 claims description 3
- 235000011178 triphosphate Nutrition 0.000 claims description 3
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims description 3
- 235000012711 vitamin K3 Nutrition 0.000 claims description 3
- 239000011652 vitamin K3 Substances 0.000 claims description 3
- 229940041603 vitamin k 3 Drugs 0.000 claims description 3
- FBZONXHGGPHHIY-UHFFFAOYSA-N xanthurenic acid Chemical compound C1=CC=C(O)C2=NC(C(=O)O)=CC(O)=C21 FBZONXHGGPHHIY-UHFFFAOYSA-N 0.000 claims description 3
- 102000000521 Immunophilins Human genes 0.000 claims description 2
- 108010016648 Immunophilins Proteins 0.000 claims description 2
- LLLPDUXGHXIXIW-UHFFFAOYSA-N N-formylanthranilic acid Chemical compound OC(=O)C1=CC=CC=C1NC=O LLLPDUXGHXIXIW-UHFFFAOYSA-N 0.000 claims description 2
- 238000006731 degradation reaction Methods 0.000 claims 3
- QEJOIGZDWKFVCO-XLPZGREQSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 QEJOIGZDWKFVCO-XLPZGREQSA-N 0.000 claims 2
- OMYMRCXOJJZYKE-UHFFFAOYSA-N 6-hydroxymelatonin Chemical compound C1=C(O)C(OC)=CC2=C1NC=C2CCNC(C)=O OMYMRCXOJJZYKE-UHFFFAOYSA-N 0.000 claims 2
- 230000003647 oxidation Effects 0.000 claims 2
- 238000007254 oxidation reaction Methods 0.000 claims 2
- 230000000063 preceeding effect Effects 0.000 claims 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 abstract description 55
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 abstract description 55
- 230000001900 immune effect Effects 0.000 abstract description 9
- 239000002207 metabolite Substances 0.000 abstract description 6
- 238000000338 in vitro Methods 0.000 description 17
- 230000014509 gene expression Effects 0.000 description 16
- 230000006698 induction Effects 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 241000700159 Rattus Species 0.000 description 11
- 239000000654 additive Substances 0.000 description 11
- 239000000427 antigen Substances 0.000 description 11
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 230000001506 immunosuppresive effect Effects 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 210000002865 immune cell Anatomy 0.000 description 8
- 230000006028 immune-suppresssive effect Effects 0.000 description 8
- 230000002480 immunoprotective effect Effects 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000003289 regulatory T cell Anatomy 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- 108010036949 Cyclosporine Proteins 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 238000001415 gene therapy Methods 0.000 description 5
- 230000008629 immune suppression Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000411 inducer Substances 0.000 description 5
- 230000008774 maternal effect Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 4
- 108010035532 Collagen Proteins 0.000 description 4
- 102100040062 Indoleamine 2,3-dioxygenase 2 Human genes 0.000 description 4
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 229960001265 ciclosporin Drugs 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 229930182912 cyclosporin Natural products 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101710120841 Indoleamine 2,3-dioxygenase 2 Proteins 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 108010074328 Interferon-gamma Proteins 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229960002986 dinoprostone Drugs 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000002650 immunosuppressive therapy Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VCKPUUFAIGNJHC-UHFFFAOYSA-N 3-hydroxykynurenine Chemical compound OC(=O)C(N)CC(=O)C1=CC=CC(O)=C1N VCKPUUFAIGNJHC-UHFFFAOYSA-N 0.000 description 2
- OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
- 108010018854 Arylformamidase Proteins 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 239000001828 Gelatine Substances 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 108010031676 Kynureninase Proteins 0.000 description 2
- 102100037652 Kynurenine 3-monooxygenase Human genes 0.000 description 2
- 108010033242 Kynurenine 3-monooxygenase Proteins 0.000 description 2
- 102100040621 Kynurenine formamidase Human genes 0.000 description 2
- 108010068073 Kynurenine-oxoglutarate transaminase Proteins 0.000 description 2
- 229940123379 Methyltransferase inhibitor Drugs 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 238000004617 QSAR study Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 108700016257 Tryptophan 2,3-dioxygenases Proteins 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 210000003027 ear inner Anatomy 0.000 description 2
- 210000000959 ear middle Anatomy 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000008344 egg yolk phospholipid Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000002388 eustachian tube Anatomy 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- CKAXPTWYSHDIBN-UHFFFAOYSA-N formyl-5-hydroxykynurenamine Chemical compound NCCC(=O)C1=CC(O)=CC=C1NC=O CKAXPTWYSHDIBN-UHFFFAOYSA-N 0.000 description 2
- 235000021588 free fatty acids Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 101150091799 ido gene Proteins 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 102000005447 kynureninase Human genes 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000009593 lumbar puncture Methods 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 210000001595 mastoid Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000003697 methyltransferase inhibitor Substances 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000005134 plasmacytoid dendritic cell Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000008347 soybean phospholipid Substances 0.000 description 2
- 210000001323 spiral ganglion Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000037351 starvation Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 210000003454 tympanic membrane Anatomy 0.000 description 2
- 210000001644 umbilical artery Anatomy 0.000 description 2
- 210000003954 umbilical cord Anatomy 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- ZADWXFSZEAPBJS-SNVBAGLBSA-N (2r)-2-amino-3-(1-methylindol-3-yl)propanoic acid Chemical compound C1=CC=C2N(C)C=C(C[C@@H](N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-SNVBAGLBSA-N 0.000 description 1
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- ACERFIHBIWMFOR-UHFFFAOYSA-N 2-hydroxy-3-[(1-hydroxy-2-methylpropan-2-yl)azaniumyl]propane-1-sulfonate Chemical compound OCC(C)(C)NCC(O)CS(O)(=O)=O ACERFIHBIWMFOR-UHFFFAOYSA-N 0.000 description 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- JTYMXXCJQKGGFG-UHFFFAOYSA-N 3-(imidazol-1-yl)lactic acid Chemical compound OC(=O)C(O)CN1C=CN=C1 JTYMXXCJQKGGFG-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 1
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 description 1
- LOJNFONOHINEFI-UHFFFAOYSA-N 4-[4-(2-hydroxyethyl)piperazin-1-yl]butane-1-sulfonic acid Chemical compound OCCN1CCN(CCCCS(O)(=O)=O)CC1 LOJNFONOHINEFI-UHFFFAOYSA-N 0.000 description 1
- RDZJLHBGYNBCPE-NTSWFWBYSA-N 4-amino-1-[(4s,5r)-4-hydroxy-5-(hydroxymethyl)-1,2-oxazolidin-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1N1O[C@H](CO)[C@@H](O)C1 RDZJLHBGYNBCPE-NTSWFWBYSA-N 0.000 description 1
- VTOWJTPBPWTSMK-UHFFFAOYSA-N 4-morpholin-4-ylbutane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1CCOCC1 VTOWJTPBPWTSMK-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 101150039504 6 gene Proteins 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- 101150035093 AMPD gene Proteins 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 description 1
- 102100021723 Arginase-1 Human genes 0.000 description 1
- 101710129000 Arginase-1 Proteins 0.000 description 1
- 102100034193 Aspartate aminotransferase, mitochondrial Human genes 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 210000005236 CD8+ effector T cell Anatomy 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000007067 DNA methylation Effects 0.000 description 1
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000004150 EU approved colour Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 229920000896 Ethulose Polymers 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 101001037261 Homo sapiens Indoleamine 2,3-dioxygenase 2 Proteins 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 1
- 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 1
- ACZFBYCNAVEFLC-UHFFFAOYSA-N Imidazole lactic acid Natural products OC(=O)C(O)CC1=CN=CN1 ACZFBYCNAVEFLC-UHFFFAOYSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000016397 Methyltransferase Human genes 0.000 description 1
- FBKMWOJEPMPVTQ-UHFFFAOYSA-N N'-(3-bromo-4-fluorophenyl)-N-hydroxy-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole-3-carboximidamide Chemical compound NS(=O)(=O)NCCNC1=NON=C1C(=NO)NC1=CC=C(F)C(Br)=C1 FBKMWOJEPMPVTQ-UHFFFAOYSA-N 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000009270 Tumour necrosis factor alpha Human genes 0.000 description 1
- 108050000101 Tumour necrosis factor alpha Proteins 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000035587 bioadhesion Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 210000004289 cerebral ventricle Anatomy 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- OGGXGZAMXPVRFZ-UHFFFAOYSA-M dimethylarsinate Chemical compound C[As](C)([O-])=O OGGXGZAMXPVRFZ-UHFFFAOYSA-M 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000028208 end stage renal disease Diseases 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000019326 ethyl hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 229940021348 methotrexate 10 mg Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000003228 microsomal effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000926 not very toxic Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- FVZVCSNXTFCBQU-UHFFFAOYSA-N phosphanyl Chemical group [PH2] FVZVCSNXTFCBQU-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229940081066 picolinic acid Drugs 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- GJAWHXHKYYXBSV-UHFFFAOYSA-N quinolinic acid Chemical compound OC(=O)C1=CC=CN=C1C(O)=O GJAWHXHKYYXBSV-UHFFFAOYSA-N 0.000 description 1
- ZADWXFSZEAPBJS-UHFFFAOYSA-N racemic N-methyl tryptophan Natural products C1=CC=C2N(C)C=C(CC(N)C(O)=O)C2=C1 ZADWXFSZEAPBJS-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000011125 single therapy Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000003019 stabilising effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 230000024664 tolerance induction Effects 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/73—Hydrolases (EC 3.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to the use of zebularine(l-( ⁇ -D-Ribofuranosyl)-l,2- dihydropyrimidin-2-one), analogue, derivative or mimetic or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3- dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.
- zebularine(l-( ⁇ -D-Ribofuranosyl)-l,2- dihydropyrimidin-2-one) analogue, derivative or mimetic or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3- dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.
- IDO Indoleamine 2,3- dioxygenase
- Organ transplantation is currently the treatment of choice for end-stage kidney, heart and liver diseases and is increasingly performed also in patients with failing other organs.
- organ transplantation despite advances in the often life-long immunosuppressive therapy and prophylaxis of infectious complications, rejection and severe infections still remain as problems after organ transplantation.
- genes are in vivo transferred into viable cells of patients or in vitro whereafter the modified cells are transplanted to the patient resulting in continued production of the corresponding proteins as long as the producing cells survive and the transferred genes are not lost or silenced, e.g. by DNA methylation.
- additional proteins related to the vector used for gene transfer are also expressed. These proteins are foreign to the patient whose immune system mounts an immune response resulting in a high risk of killing of the expressing cells and loss of effect of the gene therapy.
- autoimmune diseases are widely spread and are causing a substantial proportion of the chronical illnesses in man.
- degenerative diseases that are likely to have autoimmune components and among these can be mentioned, arteriosclerosis, Parkinson's disease, ALS (Amyotrophic lateral sclerosis), dementia.
- the immune system reacts very strongly in trauma like stroke and heart infarction and where the insult caused by lack of oxygen is enhanced by toxicity from the secondary immune reactivity. Another such situation where the immune system causes damage is after transplantation or gene therapy.
- tumour suppressor genes Genes inhibited by methylation that can favour tumour growth are tumour suppressor genes, apoptosis inducing genes, anti-angiogenetic genes, immune-stimulatory genes, and tumour antigens.
- zebularine 100-500 ⁇ M induces pl6 gene expression (Cheng et al. 2004a) and when the bladder carcinoma cells grown in BALB/c mice were treated with zebularine (500-1000 mg/kg), tumour volume was reduced, and an in vivo pi 6 gene expression was induced (Cheng et al. 2004a).
- Zebularine can also change the expression of some other genes in cancer cells such as the tumour antigen MAGE-I that is important to interact with the immune system (Cheng et al. 2004b, Liu et al. 2004.
- IDO Indoleamine 2,3-dioxygenase degrades the indole moiety of tryptophan and initiates the production of neuroactive and immunoregulatory metabolites, collectively known as kynurenines.
- the functional expression of IDO by dendritic cells has emerged in recent years as a major mechanism of peripheral tolerance. IDO contributes to maternal tolerance in pregnancy, control of allograft rejection, and protection against autoimmunity, inflammatory pathology and allergy. IDO expression also serves a physiological mechanism by which malignancies induce immune tolerance (Uyttenhove et al. 2004; Mellor et al. 2004; Munn et al 2004; ).
- the wide spectrum of physiopathological conditions in which IDO appears at work suggests that this suppressive system is frequently involved in physiological down regulation of T cell responses and resulting inflammatory responses.
- the invention relates to the use of zebularine(l-( ⁇ -D-Ribofuranosyl)-l,2- dihydropyrimidin-2-one), analogue, derivative or mimetic or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3- dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.
- Indolamine dioxygenase(IDO) produces catabolites and metabolites from tryptophan, see below.
- the medicament of the invention induces immunological tolerance in a mammal and may be used to treat a number of disorders and diseases, such as those mentioned below.
- the invention relates to the use of at least zebularine, derivative or mimetic or an analogue or salts thereof for the manufacturing of a medicament for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the treatment induces indolamine dioxygenase.
- Zebularine, derivative or mimetic or an analogue, or salts thereof may be used for the manufacturing of a medicament for the treatment of a disease selected from the group consisting of Achlorhydria, Acute hemorrhagic leukencephalitis, Addison's Disease, Alopecia Areata, Anemia, Pernicious Anti - Glomerular Basement Membrane Disease, Antiphospholipid Syndrome, Aplastic Anemia, Atopic Allergy, Autoimmune Atrophic Gastritis, Autoimmune Hearing Loss, Autoimmune hemolytic anemia, Autoimmune hypoparathyroidism, Autoimmune hypophysitis, Autoimmune Lymphoproliferative, Autoimmune Myocarditis, Autoimmune oophoritis, Autoimmune orchitis, Autoimmune Polyendocrinopathy- Candidiasis-Ectodermal-Dystrophy, Autoimmune Syndrome Type II, Polyglandular, Behcet Syndrome, Celiac Disease
- diseases that can partly be involved with autoimmune reactivity are arteriosclerosis, Parkinson's disease, and Alzheimer's disease.
- a specific group of interesting diseases and disorders includes Diabetes Mellitus Type I Rheumatoid Arthritis, Systemic Lupus Erythematosus, Chronic lymphocytic thyroiditis, Multiple Sclerosis and Ulcerative Colitis.
- Fig 1 shows the tryptophan catabolism
- EC 1.13.11.11 is tryptophan 2,3- dioxygenase
- EC 1.13.11.52 is indoleamine 2,3-dioxygenase flDO
- EC 1.14.13.9 is kynurenine 3-monooxygenase
- EC 2.6.1.7 is kynurenineoxoglutarate transaminase
- EC 3.5.1.9 is arylformamidase
- EC 3.7.1.3 is kynureninase.
- Fig 2 shows the chemical structure of zebularine.
- Fig 3 shows qRT-PCR analysis of the IDO niRNA expression levels in H1D2WT, H1D2IL12C46, and H1D2IL18C2 rat colon cancer cell lines untreated or treated with zebularine at 20 ⁇ M and lOO ⁇ M of zebularine respectively. The values given are normalized in relation to the HPRT expression values.
- Fig 4 shows zebularine treated lymphocytes.
- Fig 4A show proliferation of stimulated human lymphocytes after five days in culture in the presence of zebularine at different concentrations
- fig 4B show restoration of inhibited proliferation of stimulated human lymphocytes after five days in culture in the presence of zebularine at two different concentrations and the IDO inhibitor 1- methyl tryptophane at 100 ⁇ M
- fig 4C show proliferation of stimulated rat spleen lymphocytes after four days in culture in the presence of zebularine at different concentrations.
- immunoprotective is defined herein as an effect which reduces, arrests, or ameliorates immunological insult and is protective, resuscitative or revivative for affected tissue that has suffered cytotoxic insult from immune cells or inflammation.
- immunoprotective agent is herein defined as active ingredient or medicament containing an immune insult treatment dose of active ingredient effective in reducing, preventing, arresting, or ameliorating immune insult and provides protection, resuscitation or revival to affected tissue that has suffered immune mediated insult.
- IDO indolamine dioxygenase
- IDO-I indoleamine 2,3-dioxygenase, EC 1.13.11.52
- IDO-2 indoleamine-pyrrole 2,3 dioxygenase-like 1 , EC 1.13.11.-
- TDO tryptophan 2,3-dioxygenase, EC 1.13.11.11
- IDO- 1 can also catabolize serotonin and melatonin although the substrate specificity for IDO-2 and TDO is not so well studied.
- Metabolites or catabolites from the tryptophan pathway are Tryptophan, N-Formyl-kynurenine, Formylanthranilate, Anthranilate, L-Kynurenine, 4-(2-Aminophenyl)-2,4-dioxybutanoate, Kynurenic acid, 3-Hydroxy-L-kynurenine, 3-Hydroxy-anthranilate, 3-Metoxy-anthranilate, 4- (2-Amino-3-hydroxy-phenyl)-2,4-dioxobutanoate, Xanthurenate, 8-Metoxy- kurenate, 2-Amino-3-carboxy-muconate semialdehyde, 2-Aminomuconate semialdehyde, Quimolinic acid, Cinnavalininate, Tryptamine, N-Methyltryptamine, Indoleacetate, 2-Formamino-benzoylacetate, 5-Hydroxy
- the immune suppressive action from IDO-I, IDO-2 and TDO may be explained by 1) starvation of tryptophan, 2) direct toxic effect from several of the above mentioned metabolites/catabolites that induce apoptosis of immune cells, particularly L- Kynurenine, Anthranilate, 3-Hydroxy-anthranilate and 3-Hydroxy-L-kynurenine and 3) that some of the metabolites/catabolites stimulate the differentiation of T helper cells to immune suppressive regulatory T-cells important for tolerance.
- An analogue is a molecule that differs in chemical structure from a parent compound, for example a homolog (differing by an increment in the chemical structure, such as a difference in the length of an alkyl chain), a molecular fragment, a structure that differs by one or more functional groups, a change in ionization.
- Structural analogues are often found using quantitative structure activity relationships (QSAR) 5 with techniques such as those disclosed in Remington (The Science and Practice of Pharmacology, 19 th Edition (1995), chapter 28).
- a derivative is a substance related to a base structure, and theoretically derivable from the base structure.
- a mimetic is a biomolecule that mimics the activity of another biologically active molecule.
- Biologically active molecules can include chemical structures that mimic the biological activities of a compound, for instance zebularine.
- the IDO gene expression is known to be induced in antigen presenting cells and is subject to complex regulation by an array of signals.
- IFN- ⁇ can signal through JAK and STATl together with the sis-acting IFN- ⁇ -stimulated response elements (ISRE) on the IDO promoter, activating transcription of IDO.
- ISRE sis-acting IFN- ⁇ -stimulated response elements
- bacterial lipopolysaccharides (LPS), interleukin-1- beta (IL- 113), and TNF can also enhance IDO expression.
- IFN- ⁇ -induced IDO expression is transcriptionally enhanced by tumour necrosis factor-alpha (TNF- ⁇ ). It is possible that also an IFN- ⁇ independent induction mechanism exists.
- the invention relates to the use of at least l-( ⁇ -D-Ribofuranosyl)-l,2- dihydropyrimidin-2-one, analogue, derivative or mimetic or salts thereof for the manufacturing of a medicament for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the treatment induces indolamine dioxygenase.
- Said composition will be used as an immunoprotective agent. Examples of diseases are listed above.
- l-( ⁇ -D-Ribofuranosyl)-l,2-dihydropyrimidin-2-one also named Zebularine (Fig 2) is a drug that the inventors have shown to strongly enhance the production of IDO in concentrations of 100 ⁇ M, which is far below toxicity level.
- Zebularine will induce the production of IDO that is a natural immune suppressive molecule. As such, zebularine would help to control unwanted immune reactivity. Moreover it is likely that induction of IDO can lead to the induction of tolerance that would make continuous immunosuppressive therapy unnecessary and in this way avoid associated side effects.
- Zebularine Synonyms are l-( ⁇ -D-Ribofuranosyl)-l,2-dihydropyrimidin-2- one or 2-Pyrimidone-l- ⁇ -D-riboside.
- analogues, mimetics and derivatives that may be used include but are not limited to 5-methylcytidine, , T- deoxyzebularine, 5-fluoro-zebularine, 5-fiuoro ⁇ 2'-dexyzebularine, 5-chloro- zebularine, 5-chloro-2'-dexyzebularine, 5-bromo-zebularine, 5-bromo-2' ⁇ dexyzebularine, 5-iodo-zebularine, 5-iodo-2'-dexyzebularine, 5-methylpyrimidin-2- one, 5-Me-2'-deoxyzebularine, or mono, di or tri phosphates thereof
- the present invention is further that the invented medicament such as zebul
- Zebularine represents a completely new class of substances for use as immunomodulators for immunosuppression and tolerance induction.
- Zebularine is an immunoprotective agent at acceptable physiologic and pharmacologic doses.
- the invention is the use of for example zebularine for obtaining a treatment medicine and medicament intended for the therapeutic immunoprotective use of treating autoimmune disease and patients receiving allotransplants or undergoing gene therapy with associated risks of rejection of cells expressing the transferred genes. Examples of other diseases are found above.
- the medicament such as zebularine is suited for the immunoprotective treatment of cell cultures, in vitro treatment of transplants, transfected, genetically engineered cell cultures or transplants.
- the medicament may be administrated to a mammal in need thereof in a suitable amount to achieve an effect corresponding to such concentrations that induce a strong IDO activity in vitro of said methyl transferase inhibitor alone or in combination with other inducers of IDO.
- Other inducers of IDO can be free fatty acids, interferons, toll-like receptor ligands, histone deactylase inhibitors (HD ACi).
- the inventors investigated how zebularine, a methyl transferase inhibitor, affected the IDO production from three rat colon cancer cell lines (Fig.
- the inventors know that the 100 ⁇ M treatment of tumour cells strongly induces the production of the immunosuppressive molecule IDO but the induction of other T cell immunosuppressive molecules might also be involved, although no evidence has been found for an effect on prostaglandine E2 (PGE2) or nitric oxide (NO) production. It seems that the 100 ⁇ M zebularine treatments are not affecting the PGE2 production, the NO production, or the production of tumour antigens.
- PGE2 prostaglandine E2
- NO nitric oxide
- treatment with a dose corresponding to an in vitro dose of 5 to 1000 ⁇ M zebularine, alone or in combination with other inducers of IDO such as free fatty acids, interferons, toll- like receptor ligands or histone deactylase inhibitors (HDACi) can be used for pretreatment of transplants (organs, tissues or cells) inducing IDO expression in the endothelial cells and as a consequeence making them less immunogenic to the host and reducing the risk of rejection of the grafted cells.
- transplants organs, tissues or cells
- HDACi histone deactylase inhibitors
- Similar treatment can be used to control and even cure autoimmune diseases, such as arthritis, MS and diabetes type I by inducing tolerance to the tissue specific antigens involved.
- Zebularine is highly hydrophilic, and soluble in water. Zebularine may be administered orally or intravenously (i.v.) or by any other suitable route.
- i.v. intravenously
- the bioavailability after i.v. injection is good and about 60% of a dose of 100 mg/kg is absorbed in tissues like plasma, red blood cells, liver, kidney, spleen, heart, lung, muscle, Duodenum, Jejunum, Ileum, Colon and Carcass.
- the bioavailability for Fat, Brain, Testes, Cecum and Stomach is less. The peak concentrations are reached 5 to 10 minutes after administration and the turnover is quite fast for many tissues.
- the bioavailability has been compared to that of uridine and found to be very similar.
- Zebularine is in the mouse mainly metabolized to uridine, uracil and dihydrouracil.
- a patient is to be treated by the invented medicament such as zebularine it may be a ⁇ ninistrated in an amount which varies between 5 um to 200 uM, depending on which disease or disorder to be treated. Initially a higher dose may be used such as 75 to 1000 uM or 100 uM followed by a maintaining dose of 5-65 uM, such as 50 uM.
- the invented medicament may further comprise a pharmaceutically acceptable buffer, excipient, diluent or carrier .
- “Pharmaceutically acceptable” means a non-toxic material that does not decrease the effectiveness of the biological activity of the active ingredients.
- Such pharmaceutically acceptable buffers, carriers or excipients are well-known in the art (see Remington's Pharmaceutical Sciences, 18th edition, A.R Gennaro, Ed., Mack Publishing Company (1990) and handbook of Pharmaceutical Excipients, 3rd edition, A. Kibbe, Ed ., Pharmaceutical Press (2000).
- buffer is intended to mean an aqueous solution containing an acid-base mixture with the purpose of stabilising pH.
- buffers are Trizma, Bicine, Tricine, MOPS, MOPSO, MOBS, Tris, Hepes, HEPBS, MES, phosphate, carbonate, acetate, citrate, glycolate, lactate, borate, ACES, ADA, tartrate, AMP, AMPD, AMPSO, BES, CABS 5 cacodylate, CHES, DIPSO, EPPS, ethanolamine, glycine, HEPPSO, imidazole, imidazolelactic acid, PIPES, SSC, SSPE, POPSO, TAPS 5 TABS 5 TAPSO and TES.
- the term "diluent" is intended to mean an aqueous or non-aqueous solution with the purpose of diluting the medicament.
- the diluent may be one or more of saline, water, polyethylene glycol, propylene glycol, ethanol or oils (such as safflower oil, corn oil, peanut oil, cottonseed oil or sesame oil).
- the excipient may be one or more of carbohydrates, polymers, lipids and minerals. Examples of carbohydrates include lactose, sucrose, mannitol, and cyclodextrines, which are added to the composition, e.g.,, for facilitating lyophilisation.
- polymers are starch, cellulose ethers, cellulose carboxymethylcellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, ethylhydroxyethyl cellulose, alginates, carageenans, hyaluronic acid and derivatives thereof, polyacrylic acid, polysulphonate, polyethylenglycol/polyethylene oxide, polyethyleneoxide/polypropylene oxide copolymers, polyvinylalcohol/polyvinylacetate of different degree of hydrolysis, and polyvinylpyrrolidone, all of different molecular weight, which are added to the composition, e.g., for viscosity control, for achieving bioadhesion, or for protecting the lipid from chemical and proteolytic degradation.
- lipids are fatty acids, phospholipids, mono-, di-, and triglycerides, ceramides, sphingolipids and glycolipids, all of different acyl chain lenght and saturation, egg lecithin, soy lecithin, hydrogenated egg and soy lecithin, which are added to the composition for reasons similar to those for polymers.
- minerals are talc, magnesium oxide, zinc oxide and titanium oxide, which are added to the composition to obtain benefits such as reduction of liquid accumulation or advantageous pigment properties.
- the invented medicament may be administrated by any suitable route including oral, sublingual, buccal, nasal, inhalation, parenteral (including intraperitoneal, intraorgan, subcutaneous, intradermal, intramuscular, intra-articular, venous (central, hepatic or peripheral), lymphatic, cardiac, arterial, including selective or superselective cerebral arterial approach, retrograde perfusion through cerebral venous system, via catheter into the brain parenchyma or ventricles), direct exposure or under pressure onto or through the brain or spinal tissue, or any of the cerebrospinal fluid ventricles, injections into the subarachnoid, brain cisternal, subdural or epidural spaces, via brain cisterns or lumbar puncture, intra and periocular instillation including application by injection around the eye, within the eyeball, its structures and layers, the ear, including the Eustachian tube, mastoid air cells, external and internal auditory canals, tympanic membrane, middle ear, inner ear including the co
- the preferred route may vary depending on the condition of the patient.
- the effect of the invented medicament may be further potentiated not only by combining it with other IDO stimulating drugs as mentioned above but also in combination with an immunosuppressive agent to reduce the frequency of effector immune cells during or before the stimulation of tolerance .
- This invention includes the possibility of the timing and sequence of delivery of active ingredients to induce tolerance.
- the medicament needs to be available as soon as possible within the cells of the graft. This would induce IDO expression in endothelial cells, which by itself suppresses rejection responses.
- the medicament may comprise additional active ingredients such as glycocorticoids, methotrexate, rapamycin, cyclophosphamide, antimetabolites including azathioprine, immunophilin-binding drugs (including tolerance, tacrolimus, sirolimus, everolimus), inhibitors of nucleotide synthesis (including mycophenolate mofetil, mizoribine, leflunomide, FK778), FTY720, lymphocyte depleting antibodies (including polyclonal antibodies to lymphocytes, thymocytes, T-cells, muromonab-CD3, rituximab, Alemtuzumab, CAMPATH-I), non-depleting antibodies (including daclizumab, basiliximab, the two CTLA-4-Ig fusion proteins LEA29Y and abatacept, LFA3-Ig fusion protein), anti-TNF antibodies (including infliximab, adalimumab), natalizumab (anti-VLA
- the bioavailability of the medicament such as zebularine is partly dependent on the activity of aldehyde oxidase that can add water to the position 4 of zebularine and thereby converting zebularine into uridine.
- the activity of aldehyde oxidase is high in the liver.
- aldehyde oxidase inhibitors see Obach et al., 2004
- inhibitors with IC 50 values from 3 nM up to 1 ⁇ M are e.g., Raloxifene, Perphenazine, Thioridazine, Menadione, Trifluperazine, Amitriptyline, Estradiol, Felodipine, Clomipramine, Loratidine, Promethazine, Chlorpromazine, Ethinyl estradiol, Norclomipramine, Amodiaquine, Nortriptylin.
- the medicament includes those suitable for administration by the routes including oral, sublingual, buccal, nasal, inhalation, parenteral (including intraperitoneal, intraorgan, subcutaneous, intradermal, intramuscular, intra-articular, venous (central, hepatic or peripheral), lymphatic, cardiac, arterial, including selective or superselective cerebral arterial approach, retrograde perfusion through cerebral venous system, via catheter into the brain parenchyma or ventricles), direct exposure or under pressure onto or through the brain or spinal tissue, or any of the cerebrospinal fluid ventricles, injections into the subarachnoid, brain cisternal, subdural or epidural spaces, via brain cisterns or lumbar puncture, intra and peri- ocular instillation including application by injection around the eye, within the eyeball, its structures and layers, the ear, including the Eustachian tube, mastoid air cells, external and internal auditory canals, tympanic membrane, middle ear, inner ear including the co
- the medicament may be distributed and made available in convenient unit dose form such as capsules and ampoules, containing the active ingredient of the invention, and may be manufactured and distributed by any of the methods known to the pharmaceutical arts.
- the medicament can also contain other usual agents of the art relating to the type of medicament produced.
- This may, by example, take the configuration of suspensions, solutions and emulsions of the active ingredient in lipid, non-aqueous or aqueous diluents, solvents, dissolving agents, emulsif ⁇ ers, syrups, granulates or powders, or mixtures of these.
- the medicament can also contain colouring agents, preservatives, perfumes, flavouring additions and sweetening agents.
- the medicament can also contain other pharmaceutically active medications.
- the manufacture and distribution of the medicament is carried out by techniques known to the art, such as, evenly and intimately bringing together the active ingredient with liquids or fine solids or both, and then if needed, forming the medicament into a dose unit form.
- the discrete dose, portion and carrier vehicle constituting the medicament will generally be adapted by virtue of shape or packaging for medical administration and distributed for this purpose.
- Tablets can be manufactured and distributed by compression or mould, from active ingredient possibly with one or more additional pharmaceutically active compounds.
- Compressed tablets can be manufactured and distributed through compression in a machine typical to the art a known quantity of the active ingredient in a dispersible configuration such as powder or granules, possibly mixed with other agents including binders, lubricants, inert diluents, preservatives, and dispersing agents.
- Moulded tablets can be manufactured and distributed by moulding in a machine typical to the art a mix of known quantity of active ingredient addition pharmaceutically active compounds and other additives moistened with a liquid diluent.
- the tablets can possibly be coated, enveloped or covered, with substances including protective matrices, which can contain opacifiers or sweeteners and can be formulated to allow slow or controlled release, or also release within a certain part of the digestive system of the contained active ingredients.
- Capsules can be manufactured and distributed by placement of a known quantity of active ingredient, additional pharmaceutically active compounds and additives within a two part or sealed capsule of gelatine or other aqueous dissolvable substance.
- the active ingredient can also be manufactured and distributed as a medicament in microencapsulated, microsomal, micellar and microemulsion forms.
- the medicament containing the active ingredient acceptable for oral topical administration can be manufactured and distributed as lozenges containing the active ingredients, other pharmaceutically active compounds, and additives in a flavoured basis, such as acacia and tragacanth; Pastilles containing the active ingredient with other pharmaceutically active compounds, and additives in an inert base such as gelatine and sucrose: Mouthwashes or rinses containing the active ingredient with other pharmaceutically active compounds, and additives in an acceptable liquid.
- the medicament containing the active ingredient acceptable for skin topical administration can be manufactured and distributed as ointments, oils, creams, lotions, gels, pastes and transdermal patch containing the active ingredient, other pharmaceutically active compounds, additives and an acceptable carrier medium.
- the medicament containing the active ingredient acceptable for nasal administration can be manufactured and distributed with other pharmaceutically active compounds and additives as a powder for inhalation, or as an oily, aqueous or non-aqueous liquid for nasal spray or drops.
- the medicament containing the active ingredient acceptable for rectal administration can be manufactured and distributed as suppositories, creams, foams, douches or enemas with other pharmaceutically active compounds, suitable bases of the usual water-soluble diluents, fats, and additives known to practitioners of the art.
- the medicament containing the active ingredient acceptable for vaginal administration can be manufactured and distributed as pessaries, suppositories, creams, gels, foams, douches or sprays with other pharmaceutically active compounds, suitable bases and additives known to practitioners of the art.
- the medicament containing the active ingredient acceptable for parenteral administration can be manufactured and distributed from aqueous and non-aqueous sterile injection solutions, other pharmaceutically active compounds, additives including anti-oxidants, bacteriostats and solutes and sugars such as mannitol to make the medicament isotonic, hypotonic or hypertonic with the blood of the recipient; and also aqueous and non-aqueous sterile suspensions which can include suspenders and thickeners.
- the medicament can be manufactured and distributed in unit-dose or multi-dose containers, such as sealed glass or plastic ampoules, vials, bottles and bags as a liquid, and in a dry state requiring only the addition of sterile liquid, for example water, saline or dextrose solutions, immediately prior to use.
- sterile liquid for example water, saline or dextrose solutions
- Extemporaneous solutions and suspensions for injection can be prepared from powders and tablets of the kind above described.
- the medicament containing the active ingredient acceptable for administration into the brain and related structures, spinal cord and related structures, ventricular system and cerebrospinal fluid spaces can be manufactured and distributed from aqueous and non-aqueous sterile injection solutions, other pharmaceutically active compounds, additives including anti-oxidants, bacteriostats and solutes and sugars such as mannitol to make the medicament isotonic, hypotonic or hypertonic with the cerebrospinal fluid; and also aqueous and nonaqueous sterile suspensions which can include suspenders and thickeners.
- the medicament can be manufactured and distributed in unit-dose or multi-dose containers, such as sealed glass or plastic ampoules, vials, bottles and bags as a liquid, and in a dry state requiring only the addition of sterile liquid, for example water, saline or dextrose solutions, immediately prior to use.
- Extemporaneous solutions and suspensions for injection can be prepared from powders and tablets of the kind above described.
- the desired unit dose of medicaments are those containing a daily dose or immune insult treatment dose or an appropriate fraction thereof, of the administered active ingredient.
- Unit dose forms of the invention may also include more complex systems such as double barrelled syringes, syringes with sequential compartments one of which may contain the active ingredient, and the other any necessary diluents or vehicles.
- the agents in the syringes would be released sequentially or as a mixture or combination of the two after the triggering of the syringe plunger. Such systems are known in the art.
- the medicament may be used for the treatment of a disease or disorder such as those mentioned above.
- a disease or disorder such as those mentioned above.
- Following examples are intended to illustrate, but not to limit, the invention in any manner, shape, or form, either explicitly or implicitly.
- Example 1 Organs prepared for transplantation was perfused with cold physiological salt saline (or sodium chloride) solution containing Zebularine at a concentration of 100 ⁇ M and incubated in that solution until the surgical transplantation procedure was performed.
- cold physiological salt saline or sodium chloride
- the recipient patient is treated with oral Zebularine at an optimal dose for induction of IDO at an immunosuppressive concentration and oral cyclosporine at standard dosage continued daily for 2 weeks and at a reduced dose level for another 2 weeks.
- dexamethasone is administered intravenously at a daily dose of 8 mg and the dose is then tapered over the following 2 weeks.
- Example 2 A patient with a bilateral severe ocular-surface disorder is to receive allogeneic corneal epithelial stem-cell transplantation (as reported by Tsubota et al, NEJM, 340,1697-1703, 1999).
- One day prior to transplantation the recipient patient is treated with oral Zebularine at an optimal dose for induction of IDO at an immunosuppressive concentration and oral cyclosporine at standard dosage continued daily for 2 weeks and at a reduced dose level for another 2 weeks.
- dexamethasone is administered intravenously at a daily dose of 8 mg and the dose is then tapered over the following 2 weeks.
- Example 3 A patient suffering from critical limb ischemia is subjected to gene therapy with direct intramuscular administration of the eukaryotic expression vector pUC18 encoding VEGF 165 transcriptionally regulated by the cytomegalovirus promoter/enhancer in a total of 4 mg of DNA in 8 aliquots into the ischemic limb as previously described (Kalka et al., CIRC RES 2000; 86: 1198-1202). The day before gene transfer the patient receives oral Zebularine at an optimal dose for induction of IDO at an immunosuppressive concentration and this treatment is continued for 3 months by oral administration in order to prolong the action of the VEGF by protecting against the immune rejection of the muscle cells expressing the vector-encoded proteins. Plasma VEGF levels are measured by an ELISA assay to monitor the maintained expression of the transferred VEGF gene.
- Example 4 A patient with active Rheumatoid Arthritis with considerable remaining symptoms despite treatment with Methotrexate 10 mg per week receives oral Zebularine at an optimal dose for induction of IDO at an immunosuppressive concentration. Methotrexate therapy is continued for 6 weeks. Zebularine therapy is then continued as single therapy for 3 months in order to induce immunosuppression and immunological tolerance.
- Example 5 A patient with a diagnosis of relapsing-remitting multiple sclerosis, a score on the Expanded Disability Status Scale of 4 (on a range of 0-10), a MRI scan revealing lesions consistent with a diagnosis of multiple sclerosis, and having had a relapse despite having received treatment with interferon beta- Ia for more than 12 months at a dose of 30 microgram i.m. per week.
- oral Zebularine therapy is initiated at an optimal dose for induction of IDO at an immunosuppressive concentration.
- the interferon beta- Ia therapy is stopped after 3 weeks and Zebularine therapy continued for 12 months and then stopped provided that no relapse has occurred.
- Example 6 A young patient with the diagnosis Diabetes Mellitus type I in an early stage is treated with insulin and within 3 weeks of diagnosis with oral Zebularine at an optimal dose for induction of IDO at an immunosuppressive concentration. The required insulin dose is closely monitored beyond the expected initial decrease until it has stabilized at a low level or is no longer required. Zebularine therapy is maintained for 4 months and then stopped. Resumed Zebularine therapy dependent on a close monitoring of signs of increased requirement of insulin.
- Example 7 Immune cells treated with zebularine in vitro (The use of in vitro treatment of immune cells with zebularine) can be utilized for transplantation.
- Peripheral blood from a patient with diabetes type I who is to receive a (that will be given) pancreatic beta cell transplant (transplantation) is collected.
- White blood cells from the patient blood are isolated and cultured in the presence of GMCSF, protein extract from the donor and zebularine.
- the cells are then stimulated with CpG-containing oligonucleotides and after further culture in vitro in presence of zebularine and HDAC inhibitors, regulatory plasmacytoid dendritic cells are enriched and are given back to the patient.
- the in vitro treatment can also be combined with e.g., treatment with CTLA4-Ig or HDAC inhibitors.
- These regulatory DC will then present antigens from the donor and induce tolerance against these foreign antigens.
- the beta cells from the donor are treated in vitro with zebularine prior to tranplantation.
- the patient can be given a pretreatment with zebularine, alone or in combination with HDAC-inhibitors, rapamycin, CTLA4-Ig, alone or in combination).
- the in vivo treatment will continue for about 2 weeks after transplantation of the pancreatic, insulin producing beta-cells.
- the patient is monitored by FACS analysis for presence of FoxP3 regulatory T-cells having T- cell receptors that can bind beta cell peptides conjugated with soluble fluorescent HLA-DR complexes.
- FACS fluorescence activated cell sorter
- Example 8 Immune cells treated with zebularine in vitro (The use of in vitro treatment of immune cells with zebularine) can be utilized in patients with autoimmune disease (for autoimmunity).
- Peripheral blood from a patient with reumatoid arthritis is collected.
- White blood cells from the patient blood are isolated and cultured in the presence of GMCSF, collagen or cartilage and zebularine.
- the cells are then stimulated with CpG-containing oligonucleotides and after further culture in vitro in presence of zebularine and HDAC inhibitors, regulatory plasmacytoid dendritic cells are enriched and are given back to the patient.
- the in vitro treatment can also be combined with e.g., treatment with CTLA4-Ig or HDAC inhibitors.
- These regulatory DC will then present antigens from collagen and reinduce (induce) tolerance against these self antigens (that is broken) in the RA patient.
- the patient can be given a pretreatment with zebularine, alone or in combination with HDAC-inhibitors, rapamycin, CTLA4-Ig (alone or in combination).
- In vivo treatment will continue for about 2 weeks after injection of the in vitro treated tolerogenic DC cells.
- the patient is monitored by FACS analysis for presence of FoxP3 regulatory T-cells having T-cell receptors that can bind collagen peptides conjugated with soluble fluorescent HLA-DR complexes.
- the patient is also monitored for the presence of CD8+ effector T-cells with TcR that can bind soluble fluorescent HLA-A proteins conjugated with collagen peptides.
- TcR fluorescence activated cell sorter
- FACS fluorescence activated cell sorter
- Example 9 In an experiment the inventors tested the immunogenicity of genetically engineered rat colon cancer cells expressing rat interleukin 12. These cancer cells have repeteadly been used to immunize rats that create a strong immune response towards the rat tumour cells. The inventors pre-treated these rat colon cancer cells with 100 ⁇ M zebularine that rendered the rat colon cancer cells less immunogenic when used for immunization. This was congruent with the changes in expression of IDO (Fig. 3). Similar treatments of rat spleen cells and human buffy coat leukocytes induce enhanced IDO production and strong suppression of polyclonal lymphocyte proliferation, i.e. suppression of T cell activation.
- Liu, G. , H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, J. S. Yu, HER-2, gplOO, and MAGE-I are expressed in human glioblastoma and recognized by cytotoxic T cells, Cancer Research, 64 (2004) 4980-4986.
- Oxidase Inhibition by 239 Drugs. Journal of Clinical Pharmacology, 2004; 44:7-19
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
Abstract
The invention relates to the use of l-(β-D-Ribofuranosyl)-l,2- dihydropyrimidin-2-one derivative or mimetic or an analogue, derivatives, metabolites, variants or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3-dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.
Description
The use of Zeburaline for the treatment of autoimmune diseases or immune rejection of transplants
FIELD OF INVENTION
The invention relates to the use of zebularine(l-(β-D-Ribofuranosyl)-l,2- dihydropyrimidin-2-one), analogue, derivative or mimetic or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3- dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof.
BACKGROUND OF INVENTION
Organ transplantation is currently the treatment of choice for end-stage kidney, heart and liver diseases and is increasingly performed also in patients with failing other organs. However, despite advances in the often life-long immunosuppressive therapy and prophylaxis of infectious complications, rejection and severe infections still remain as problems after organ transplantation. In gene therapy, genes are in vivo transferred into viable cells of patients or in vitro whereafter the modified cells are transplanted to the patient resulting in continued production of the corresponding proteins as long as the producing cells survive and the transferred genes are not lost or silenced, e.g. by DNA methylation. As a rule additional proteins related to the vector used for gene transfer are also expressed. These proteins are foreign to the patient whose immune system mounts an immune response resulting in a high risk of killing of the expressing cells and loss of effect of the gene therapy.
It is well recognized that the optimal way of avoiding these problems of rejection of cells or organs expressing foreign antigens is to induce immunological tolerance to these antigens. In cases where an antigen selective non-responsiveness is physiologically developing, it is often dependent on a functioning IDO and administration of inhibitors of IDO breaks the state of unresponsiveness (Miki et al., 2001). Transfer of the IDO gene into allogeneic cells can lead to over expression of IDO and has been reported to result in a strong suppression of the rejection response to the allografts and permanent survival of the transferred cells without supporting immunosuppressive therapy.
Autoimmune diseases are widely spread and are causing a substantial proportion of the chronical illnesses in man. There is a great number of different autoimmune diseases, the most common being Rheumatoid arthritis, Diabetes type I, Psoriasis, Sjδgrens syndrome, Multiple Sclerosis (MS), Crohns disease. There also exists a number of degenerative diseases that are likely to have autoimmune components and among these can be mentioned, arteriosclerosis, Parkinson's disease, ALS (Amyotrophic lateral sclerosis), dementia. In addition, there are
situations when the immune system reacts very strongly in trauma like stroke and heart infarction and where the insult caused by lack of oxygen is enhanced by toxicity from the secondary immune reactivity. Another such situation where the immune system causes damage is after transplantation or gene therapy. The rejection of the transplant is mediated by the immune system and transplanted or genetically treated patients need rather strong immune suppressive drugs for the rest of there lives and these immune suppressive drugs cause several severe side effects. Zebularine is a cytidine analogue, and a DNA methyl transferase inhibitor that has been shown to be stable and not very toxic compared to azacytidine or 2'-deoxy- azacytidine (Cheng et al. 2003). Inhibitors of DNA methyl transferases have been used in preclinical and clinical trials as therapies against cancer. Genes inhibited by methylation that can favour tumour growth are tumour suppressor genes, apoptosis inducing genes, anti-angiogenetic genes, immune-stimulatory genes, and tumour antigens. In human bladder cancer cells, zebularine (100-500 μM) induces pl6 gene expression (Cheng et al. 2004a) and when the bladder carcinoma cells grown in BALB/c mice were treated with zebularine (500-1000 mg/kg), tumour volume was reduced, and an in vivo pi 6 gene expression was induced (Cheng et al. 2004a). Zebularine can also change the expression of some other genes in cancer cells such as the tumour antigen MAGE-I that is important to interact with the immune system (Cheng et al. 2004b, Liu et al. 2004.
Indoleamine 2,3-dioxygenase (IDO) degrades the indole moiety of tryptophan and initiates the production of neuroactive and immunoregulatory metabolites, collectively known as kynurenines. The functional expression of IDO by dendritic cells has emerged in recent years as a major mechanism of peripheral tolerance. IDO contributes to maternal tolerance in pregnancy, control of allograft rejection, and protection against autoimmunity, inflammatory pathology and allergy. IDO expression also serves a physiological mechanism by which malignancies induce immune tolerance (Uyttenhove et al. 2004; Mellor et al. 2004; Munn et al 2004; ). The wide spectrum of physiopathological conditions in which IDO appears at work suggests that this suppressive system is frequently involved in physiological down regulation of T cell responses and resulting inflammatory responses.
SUMMARY OF THE INVENTION The invention relates to the use of zebularine(l-(β-D-Ribofuranosyl)-l,2- dihydropyrimidin-2-one), analogue, derivative or mimetic or salts thereof for the manufacturing of a medicament to increase the amount of Indoleamine 2,3- dioxygenase (IDO) production in order to induce immunological tolerance as well as a method of treating a mammal in need thereof. Indolamine dioxygenase(IDO)
produces catabolites and metabolites from tryptophan, see below. The medicament of the invention induces immunological tolerance in a mammal and may be used to treat a number of disorders and diseases, such as those mentioned below.
Additionally, the invention relates to the use of at least zebularine, derivative or mimetic or an analogue or salts thereof for the manufacturing of a medicament for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the treatment induces indolamine dioxygenase.
By providing such a medicament it is possible for the first time to induce immunological tolerance in an efficient way and thereby to enable the possibility to treat a number of diseases as defined below.
Zebularine, derivative or mimetic or an analogue, or salts thereof may be used for the manufacturing of a medicament for the treatment of a disease selected from the group consisting of Achlorhydria, Acute hemorrhagic leukencephalitis, Addison's Disease, Alopecia Areata, Anemia, Pernicious Anti - Glomerular Basement Membrane Disease, Antiphospholipid Syndrome, Aplastic Anemia, Atopic Allergy, Autoimmune Atrophic Gastritis, Autoimmune Hearing Loss, Autoimmune hemolytic anemia, Autoimmune hypoparathyroidism, Autoimmune hypophysitis, Autoimmune Lymphoproliferative, Autoimmune Myocarditis, Autoimmune oophoritis, Autoimmune orchitis, Autoimmune Polyendocrinopathy- Candidiasis-Ectodermal-Dystrophy, Autoimmune Syndrome Type II, Polyglandular, Behcet Syndrome, Celiac Disease, Chagas Disease, Cholangitis, Sclerosing, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic lymphocytic thyroiditis, Churg - Strauss Syndrome, Colitis, Ulcerative, Crohn's disease, Cryoglobulinemia, Gushing Syndrome, Dermatitis Herpetiformis, Dermatomyositis, Diabetes Mellitus (Insulin - Dependent), Diffuse Cerebral Sclerosis of Schilder, Encephalomyelitis, Autoimmune, Experimental (EAE), Epidermolysis Bullosa Acquisita, Erythematosis, Felty's Syndrome, Glomerulonephritis (IGA), Glomerulonephritis Membranous, Goodpasture Syndrome, Graves' Disease, Guillain - Barre Syndrome, Hamman-Rich syndrome, Hepatitis Autoimmune, Hepatitis Chronic Active, Idiopathic thrombocytopenia, Inflammatory Bowel Diseases, Insulin resistance - type B, Lambert - Eaton Myasthenic Syndrome, Lens-induced uveitis, Lichen Sclerosus et Atrophicus, Lupus Erythematosus Discoid, Lupus Erythematosus Systemic, Lupus Hepatitis, Lupus Nephritis, Lymphopenia, Meniere's Disease, Mixed Connective Tissue Disease, Mooren's ulcer, Mucocutaneous Lymph Node Syndrome, Multiple Sclerosis, Myasthenia Gravis, Myelitis Transverse, Myocarditis, Narcolepsy, Neuritis Autoimmune Experimental, Neuromyelitis Optica, Oculovestibuloauditory syndrome, Ophthalmia Sympathetic, Opsoclonus - Myoclonus Syndrome,
Pancreatitis, Pemphigoid Bullous, Pemphigus foliaceous, Pemphigus Vulgaris, Polyarteritis Nodosa, Polychondritis Relapsing, Polyendocrinopathies Autoimmune, Polymyalgia Rheumatica, Polyradiculoneuropathy, Primary biliary cirrhosis, Psoriasis, Purpura Thrombocytopenic Idiopathic, Raynauds, Reiter Disease, Rheumatic Fever, Rheumatoid Arthritis, Sarcoidosis, Scleroderma, Sjogren's Syndrome, Spondylitis Ankylosing, Stiff - Person Syndrome, Still's Disease Adult Onset, Takayasu's Arteritis, Temporal Arteritis, Thyrotoxicosis, Type B Insulin Resistance, Uveomeningoencephalitic Syndrome, Wegener's Granulomatosis, Vitiligo. In addition diseases that can partly be involved with autoimmune reactivity are arteriosclerosis, Parkinson's disease, and Alzheimer's disease. A specific group of interesting diseases and disorders includes Diabetes Mellitus Type I Rheumatoid Arthritis, Systemic Lupus Erythematosus, Chronic lymphocytic thyroiditis, Multiple Sclerosis and Ulcerative Colitis.
Alternatively it may be used for the manufacturing of a medicament to be used in transplantations to inhibit immune rejection of organs, tissues, normal or gene therapeutically modified cells
BRIEF DESCRIPTION OF THE DRAWINGS
Fig 1 shows the tryptophan catabolism, EC 1.13.11.11 is tryptophan 2,3- dioxygenase, EC 1.13.11.52 is indoleamine 2,3-dioxygenase flDO), EC 1.14.13.9 is kynurenine 3-monooxygenase, EC 2.6.1.7 is kynurenineoxoglutarate transaminase, EC 3.5.1.9 is arylformamidase and EC 3.7.1.3 is kynureninase. Fig 2 shows the chemical structure of zebularine. Fig 3 shows qRT-PCR analysis of the IDO niRNA expression levels in H1D2WT, H1D2IL12C46, and H1D2IL18C2 rat colon cancer cell lines untreated or treated with zebularine at 20 μM and lOOμM of zebularine respectively. The values given are normalized in relation to the HPRT expression values.
Fig 4 shows zebularine treated lymphocytes. Fig 4A show proliferation of stimulated human lymphocytes after five days in culture in the presence of zebularine at different concentrations, fig 4B show restoration of inhibited proliferation of stimulated human lymphocytes after five days in culture in the presence of zebularine at two different concentrations and the IDO inhibitor 1- methyl tryptophane at 100 μM and fig 4C show proliferation of stimulated rat spleen lymphocytes after four days in culture in the presence of zebularine at different concentrations.
DETAILED DESCRIPTION OF THE INVENTION
In the context of the present application and invention, the following definitions apply:
The term "immunoprotective" is defined herein as an effect which reduces, arrests, or ameliorates immunological insult and is protective, resuscitative or revivative for affected tissue that has suffered cytotoxic insult from immune cells or inflammation.
The term "immunoprotective agent" is herein defined as active ingredient or medicament containing an immune insult treatment dose of active ingredient effective in reducing, preventing, arresting, or ameliorating immune insult and provides protection, resuscitation or revival to affected tissue that has suffered immune mediated insult.
The term "indolamine dioxygenase (IDO)" is intended to mean IDO-I (indoleamine 2,3-dioxygenase, EC 1.13.11.52), IDO-2 (indoleamine-pyrrole 2,3 dioxygenase-like 1 , EC 1.13.11.-) or TDO (tryptophan 2,3-dioxygenase, EC 1.13.11.11) that are three different proteins that can catabolize tryptophan. IDO- 1 can also catabolize serotonin and melatonin although the substrate specificity for IDO-2 and TDO is not so well studied. Metabolites or catabolites from the tryptophan pathway are Tryptophan, N-Formyl-kynurenine, Formylanthranilate, Anthranilate, L-Kynurenine, 4-(2-Aminophenyl)-2,4-dioxybutanoate, Kynurenic acid, 3-Hydroxy-L-kynurenine, 3-Hydroxy-anthranilate, 3-Metoxy-anthranilate, 4- (2-Amino-3-hydroxy-phenyl)-2,4-dioxobutanoate, Xanthurenate, 8-Metoxy- kurenate, 2-Amino-3-carboxy-muconate semialdehyde, 2-Aminomuconate semialdehyde, Quimolinic acid, Cinnavalininate, Tryptamine, N-Methyltryptamine, Indoleacetate, 2-Formamino-benzoylacetate, 5-Hydroxy-L-tryptophan, 5-Hydroxy- N-formylkunerine, 5-Hydroxy-kunerine, 5-Hydroxy-kunerenamin, 4,6-Dihydroxy- quinoline, Serotonin, N-Acetyl-serotonin, Melatonin, 6-Hydroxy-melatonin, Foiτnyl-N-acetyl-5-metoxykynurenamine, N-Methylserotonin, Formyl-5-hydroxy- kynurenamine, 5-Metoxytryptamine, 5-Hydroxyindole-acetaldehyde, 5- Hydroxyindoleacetate, 5-Metoxyindoleacetate, or 5-Hydroxyindole-acetylglycine to enhance the immunosuppressive IDO activity. Examples are Kynurenine, 3- hydroxy-kynurenine, anthranilic acid, 3-hydroxy-anthranilic acid, quinolinic acid and picolinic acid. Also enhancements using synthetic variants of tryptophan catabolites, e.g., N-(3,4,-Dimethoxycinnamoyl) anthranilic acid. The immune suppression mediated by IDO is mediated by starvation of
Tryptophan, induction of apoptosis in lymphocytes and induction of regulatory T lymphocytes (Treg). Hence, the apoptosis induction and Treg induction is mediated by the catabolites, why addition of such catabolites in combination with IDO induction by medicament of the invention may enhance the clinical effect. The
immune suppressive action from IDO-I, IDO-2 and TDO may be explained by 1) starvation of tryptophan, 2) direct toxic effect from several of the above mentioned metabolites/catabolites that induce apoptosis of immune cells, particularly L- Kynurenine, Anthranilate, 3-Hydroxy-anthranilate and 3-Hydroxy-L-kynurenine and 3) that some of the metabolites/catabolites stimulate the differentiation of T helper cells to immune suppressive regulatory T-cells important for tolerance.
An analogue is a molecule that differs in chemical structure from a parent compound, for example a homolog (differing by an increment in the chemical structure, such as a difference in the length of an alkyl chain), a molecular fragment, a structure that differs by one or more functional groups, a change in ionization. Structural analogues are often found using quantitative structure activity relationships (QSAR)5 with techniques such as those disclosed in Remington (The Science and Practice of Pharmacology, 19th Edition (1995), chapter 28). A derivative is a substance related to a base structure, and theoretically derivable from the base structure. A mimetic is a biomolecule that mimics the activity of another biologically active molecule. Biologically active molecules can include chemical structures that mimic the biological activities of a compound, for instance zebularine.
The IDO gene expression is known to be induced in antigen presenting cells and is subject to complex regulation by an array of signals. For example, IFN-γ can signal through JAK and STATl together with the sis-acting IFN-γ-stimulated response elements (ISRE) on the IDO promoter, activating transcription of IDO. However, bacterial lipopolysaccharides (LPS), interleukin-1- beta (IL- 113), and TNF can also enhance IDO expression. Also in human epithelial cells, IFN-γ-induced IDO expression is transcriptionally enhanced by tumour necrosis factor-alpha (TNF-α). It is possible that also an IFN-γindependent induction mechanism exists.
The invention relates to the use of at least l-(β-D-Ribofuranosyl)-l,2- dihydropyrimidin-2-one, analogue, derivative or mimetic or salts thereof for the manufacturing of a medicament for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the treatment induces indolamine dioxygenase. Said composition will be used as an immunoprotective agent. Examples of diseases are listed above. l-(β-D-Ribofuranosyl)-l,2-dihydropyrimidin-2-one also named Zebularine (Fig 2) is a drug that the inventors have shown to strongly enhance the production of IDO in concentrations of 100 μM, which is far below toxicity level.
Zebularine will induce the production of IDO that is a natural immune suppressive molecule. As such, zebularine would help to control unwanted immune reactivity. Moreover it is likely that induction of IDO can lead to the induction of
tolerance that would make continuous immunosuppressive therapy unnecessary and in this way avoid associated side effects.
Another name of zebularine is
2'-(9-^Butyldimethylsilyl-3'-O-[(di-isopropylamino)(2-cyanoethoxy)phosphino]- 5'-O-(4,4'-dimemoxytrityl)-2(lH)-pyrimidinone-l-β-D-riboside3 zebularine, is a useful and effective inducer of immune suppression and inducer of the IDO production. The chemical structure of Zebularine is shown in Fig 2.
Zebularine Synonyms are l-(β-D-Ribofuranosyl)-l,2-dihydropyrimidin-2- one or 2-Pyrimidone-l-β-D-riboside. Examples of analogues, mimetics and derivatives that may be used include but are not limited to 5-methylcytidine, , T- deoxyzebularine, 5-fluoro-zebularine, 5-fiuoro~2'-dexyzebularine, 5-chloro- zebularine, 5-chloro-2'-dexyzebularine, 5-bromo-zebularine, 5-bromo-2'~ dexyzebularine, 5-iodo-zebularine, 5-iodo-2'-dexyzebularine, 5-methylpyrimidin-2- one, 5-Me-2'-deoxyzebularine, or mono, di or tri phosphates thereof The present invention is further that the invented medicament such as zebularine containing an immunoprotective treatment dose of active ingredients aimed as an agents in situations where autoimmune reactivity is involved in the central nervous system, such as the diseases mentioned above.
Zebularine represents a completely new class of substances for use as immunomodulators for immunosuppression and tolerance induction. Zebularine is an immunoprotective agent at acceptable physiologic and pharmacologic doses.
The invention is the use of for example zebularine for obtaining a treatment medicine and medicament intended for the therapeutic immunoprotective use of treating autoimmune disease and patients receiving allotransplants or undergoing gene therapy with associated risks of rejection of cells expressing the transferred genes. Examples of other diseases are found above.
The medicament, such as zebularine is suited for the immunoprotective treatment of cell cultures, in vitro treatment of transplants, transfected, genetically engineered cell cultures or transplants. The medicament may be administrated to a mammal in need thereof in a suitable amount to achieve an effect corresponding to such concentrations that induce a strong IDO activity in vitro of said methyl transferase inhibitor alone or in combination with other inducers of IDO. Other inducers of IDO can be free fatty acids, interferons, toll-like receptor ligands, histone deactylase inhibitors (HD ACi). The inventors investigated how zebularine, a methyl transferase inhibitor, affected the IDO production from three rat colon cancer cell lines (Fig. 3) , and found that the IDO expression dramatically increased at a zebularine concentration of 100 μM. The treatment with 100 μM of zebularine induced IDO mRNA expression in all three cell lines. A 48-fold increase of the IDO mRNA level in the
H1D2WT cell line, a 24-fold increase in the H1D2IL12C46 cell line and a 14-fold increase in the H1D2IL18C2 cell line were detected. Immunization of rats with tumour cells pretreated with 100 μM of zebularine also resulted in a very weak proliferative response of non-adherent spleen cells stimulated with tumor cells in vitro. The inventors know that the 100 μM treatment of tumour cells strongly induces the production of the immunosuppressive molecule IDO but the induction of other T cell immunosuppressive molecules might also be involved, although no evidence has been found for an effect on prostaglandine E2 (PGE2) or nitric oxide (NO) production. It seems that the 100 μM zebularine treatments are not affecting the PGE2 production, the NO production, or the production of tumour antigens.
By having a direct effect on the immune system, treatment with a dose corresponding to an in vitro dose of 5 to 1000 μM zebularine, alone or in combination with other inducers of IDO such as free fatty acids, interferons, toll- like receptor ligands or histone deactylase inhibitors (HDACi) can be used for pretreatment of transplants (organs, tissues or cells) inducing IDO expression in the endothelial cells and as a consequeence making them less immunogenic to the host and reducing the risk of rejection of the grafted cells. By subsequent treatment of the graft recipients with zebularine at a dose providing immune suppression in vivo and induction of immunological tolerance permanent survival of the transplants can be achieved without further therapy or with minimal such therapy.
Similar treatment can be used to control and even cure autoimmune diseases, such as arthritis, MS and diabetes type I by inducing tolerance to the tissue specific antigens involved.
Zebularine is highly hydrophilic, and soluble in water. Zebularine may be administered orally or intravenously (i.v.) or by any other suitable route. In the mouse, the bioavailability after i.v. injection is good and about 60% of a dose of 100 mg/kg is absorbed in tissues like plasma, red blood cells, liver, kidney, spleen, heart, lung, muscle, Duodenum, Jejunum, Ileum, Colon and Carcass. The bioavailability for Fat, Brain, Testes, Cecum and Stomach is less. The peak concentrations are reached 5 to 10 minutes after administration and the turnover is quite fast for many tissues. The bioavailability has been compared to that of uridine and found to be very similar.
Zebularine is in the mouse mainly metabolized to uridine, uracil and dihydrouracil. When a patient is to be treated by the invented medicament such as zebularine it may be aώninistrated in an amount which varies between 5 um to 200 uM, depending on which disease or disorder to be treated. Initially a higher dose may be used such as 75 to 1000 uM or 100 uM followed by a maintaining dose of 5-65 uM, such as 50 uM.
The invented medicament may further comprise a pharmaceutically acceptable buffer, excipient, diluent or carrier .
"Pharmaceutically acceptable" means a non-toxic material that does not decrease the effectiveness of the biological activity of the active ingredients.. Such pharmaceutically acceptable buffers, carriers or excipients are well-known in the art (see Remington's Pharmaceutical Sciences, 18th edition, A.R Gennaro, Ed., Mack Publishing Company (1990) and handbook of Pharmaceutical Excipients, 3rd edition, A. Kibbe, Ed ., Pharmaceutical Press (2000).
The term "buffer" is intended to mean an aqueous solution containing an acid-base mixture with the purpose of stabilising pH. Examples of buffers are Trizma, Bicine, Tricine, MOPS, MOPSO, MOBS, Tris, Hepes, HEPBS, MES, phosphate, carbonate, acetate, citrate, glycolate, lactate, borate, ACES, ADA, tartrate, AMP, AMPD, AMPSO, BES, CABS5 cacodylate, CHES, DIPSO, EPPS, ethanolamine, glycine, HEPPSO, imidazole, imidazolelactic acid, PIPES, SSC, SSPE, POPSO, TAPS5 TABS5 TAPSO and TES.
The term "diluent" is intended to mean an aqueous or non-aqueous solution with the purpose of diluting the medicament. The diluent may be one or more of saline, water, polyethylene glycol, propylene glycol, ethanol or oils (such as safflower oil, corn oil, peanut oil, cottonseed oil or sesame oil). The excipient may be one or more of carbohydrates, polymers, lipids and minerals. Examples of carbohydrates include lactose, sucrose, mannitol, and cyclodextrines, which are added to the composition, e.g.,, for facilitating lyophilisation. Examples of polymers are starch, cellulose ethers, cellulose carboxymethylcellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, ethylhydroxyethyl cellulose, alginates, carageenans, hyaluronic acid and derivatives thereof, polyacrylic acid, polysulphonate, polyethylenglycol/polyethylene oxide, polyethyleneoxide/polypropylene oxide copolymers, polyvinylalcohol/polyvinylacetate of different degree of hydrolysis, and polyvinylpyrrolidone, all of different molecular weight, which are added to the composition, e.g., for viscosity control, for achieving bioadhesion, or for protecting the lipid from chemical and proteolytic degradation. Examples of lipids are fatty acids, phospholipids, mono-, di-, and triglycerides, ceramides, sphingolipids and glycolipids, all of different acyl chain lenght and saturation, egg lecithin, soy lecithin, hydrogenated egg and soy lecithin, which are added to the composition for reasons similar to those for polymers. Examples of minerals are talc, magnesium oxide, zinc oxide and titanium oxide, which are added to the composition to obtain benefits such as reduction of liquid accumulation or advantageous pigment properties.
The invented medicament may be administrated by any suitable route
including oral, sublingual, buccal, nasal, inhalation, parenteral (including intraperitoneal, intraorgan, subcutaneous, intradermal, intramuscular, intra-articular, venous (central, hepatic or peripheral), lymphatic, cardiac, arterial, including selective or superselective cerebral arterial approach, retrograde perfusion through cerebral venous system, via catheter into the brain parenchyma or ventricles), direct exposure or under pressure onto or through the brain or spinal tissue, or any of the cerebrospinal fluid ventricles, injections into the subarachnoid, brain cisternal, subdural or epidural spaces, via brain cisterns or lumbar puncture, intra and periocular instillation including application by injection around the eye, within the eyeball, its structures and layers, the ear, including the Eustachian tube, mastoid air cells, external and internal auditory canals, tympanic membrane, middle ear, inner ear including the cochlear spiral ganglion and labyrinthine organs, as well as via enteral, bowel, rectal, vaginal, urethral or bladder cisternal. Also for in utero and perinatal indications then injections into the maternal vasculature, or through or into maternal organs including the uterus, cervix and vagina, and into embryo, foetus, neonate and allied tissues and spaces such as the amniotic sac, the umbilical cord, the umbilical artery or veins and the placenta, with parenteral being the preferred route. The preferred route may vary depending on the condition of the patient.
The effect of the invented medicament may be further potentiated not only by combining it with other IDO stimulating drugs as mentioned above but also in combination with an immunosuppressive agent to reduce the frequency of effector immune cells during or before the stimulation of tolerance .
This invention includes the possibility of the timing and sequence of delivery of active ingredients to induce tolerance. In order to have the best opportunity to protect tissue from immune mediated insult, the medicament needs to be available as soon as possible within the cells of the graft. This would induce IDO expression in endothelial cells, which by itself suppresses rejection responses.
The medicament may comprise additional active ingredients such as glycocorticoids, methotrexate, rapamycin, cyclophosphamide, antimetabolites including azathioprine, immunophilin-binding drugs (including tolerance, tacrolimus, sirolimus, everolimus), inhibitors of nucleotide synthesis (including mycophenolate mofetil, mizoribine, leflunomide, FK778), FTY720, lymphocyte depleting antibodies (including polyclonal antibodies to lymphocytes, thymocytes, T-cells, muromonab-CD3, rituximab, Alemtuzumab, CAMPATH-I), non-depleting antibodies (including daclizumab, basiliximab, the two CTLA-4-Ig fusion proteins LEA29Y and abatacept, LFA3-Ig fusion protein), anti-TNF antibodies (including infliximab, adalimumab), natalizumab (anti-VLA-4), the anti-CD 154 antibodies BG9588 and IDEC 131), soluble cytokine receptors (including lenercept and
etanercept (soluble TNF p55 and TNF p75 receptors), histone deacetylase inhibitors and anakinra (soluble IL-IRA).
Other examples includes transfer of genes such as arginase-1, or substances like prostaglandin E2 (PGE2), cyclosporine A. These immune suppressive drugs mentioned above can be used in combination with the medicament of the invention to reduce the number of immune cells.
The bioavailability of the medicament such as zebularine is partly dependent on the activity of aldehyde oxidase that can add water to the position 4 of zebularine and thereby converting zebularine into uridine. The activity of aldehyde oxidase is high in the liver. There exist a large number of aldehyde oxidase inhibitors (see Obach et al., 2004) and inhibitors with IC50 values from 3 nM up to 1 μM are e.g., Raloxifene, Perphenazine, Thioridazine, Menadione, Trifluperazine, Amitriptyline, Estradiol, Felodipine, Clomipramine, Loratidine, Promethazine, Chlorpromazine, Ethinyl estradiol, Norclomipramine, Amodiaquine, Nortriptylin.
The medicament includes those suitable for administration by the routes including oral, sublingual, buccal, nasal, inhalation, parenteral (including intraperitoneal, intraorgan, subcutaneous, intradermal, intramuscular, intra-articular, venous (central, hepatic or peripheral), lymphatic, cardiac, arterial, including selective or superselective cerebral arterial approach, retrograde perfusion through cerebral venous system, via catheter into the brain parenchyma or ventricles), direct exposure or under pressure onto or through the brain or spinal tissue, or any of the cerebrospinal fluid ventricles, injections into the subarachnoid, brain cisternal, subdural or epidural spaces, via brain cisterns or lumbar puncture, intra and peri- ocular instillation including application by injection around the eye, within the eyeball, its structures and layers, the ear, including the Eustachian tube, mastoid air cells, external and internal auditory canals, tympanic membrane, middle ear, inner ear including the cochlear spiral ganglion and labyrinthine organs, as well as via enteral, bowel, rectal, vaginal, urethral or bladder cisternal. Also for in utero and perinatal indications then injections into the maternal vasculature, or through or into maternal organs including the uterus, cervix and vagina, and into embryo, fetus, neonate and allied tissues and spaces such as the amniotic sac, the umbilical cord, the umbilical artery or veins and the placenta, with parenteral being the preferred route. The medicament may be distributed and made available in convenient unit dose form such as capsules and ampoules, containing the active ingredient of the invention, and may be manufactured and distributed by any of the methods known to the pharmaceutical arts. In addition to the active ingredient, the medicament can also contain other usual agents of the art relating to the type of medicament
produced. This may, by example, take the configuration of suspensions, solutions and emulsions of the active ingredient in lipid, non-aqueous or aqueous diluents, solvents, dissolving agents, emulsifϊers, syrups, granulates or powders, or mixtures of these. The medicament can also contain colouring agents, preservatives, perfumes, flavouring additions and sweetening agents. In addition to the active ingredient, the medicament can also contain other pharmaceutically active medications. The manufacture and distribution of the medicament is carried out by techniques known to the art, such as, evenly and intimately bringing together the active ingredient with liquids or fine solids or both, and then if needed, forming the medicament into a dose unit form. The discrete dose, portion and carrier vehicle constituting the medicament will generally be adapted by virtue of shape or packaging for medical administration and distributed for this purpose.
Tablets can be manufactured and distributed by compression or mould, from active ingredient possibly with one or more additional pharmaceutically active compounds. Compressed tablets can be manufactured and distributed through compression in a machine typical to the art a known quantity of the active ingredient in a dispersible configuration such as powder or granules, possibly mixed with other agents including binders, lubricants, inert diluents, preservatives, and dispersing agents. Moulded tablets can be manufactured and distributed by moulding in a machine typical to the art a mix of known quantity of active ingredient addition pharmaceutically active compounds and other additives moistened with a liquid diluent. The tablets can possibly be coated, enveloped or covered, with substances including protective matrices, which can contain opacifiers or sweeteners and can be formulated to allow slow or controlled release, or also release within a certain part of the digestive system of the contained active ingredients. Capsules can be manufactured and distributed by placement of a known quantity of active ingredient, additional pharmaceutically active compounds and additives within a two part or sealed capsule of gelatine or other aqueous dissolvable substance. The active ingredient can also be manufactured and distributed as a medicament in microencapsulated, microsomal, micellar and microemulsion forms.
The medicament containing the active ingredient acceptable for oral topical administration can be manufactured and distributed as lozenges containing the active ingredients, other pharmaceutically active compounds, and additives in a flavoured basis, such as acacia and tragacanth; Pastilles containing the active ingredient with other pharmaceutically active compounds, and additives in an inert base such as gelatine and sucrose: Mouthwashes or rinses containing the active ingredient with other pharmaceutically active compounds, and additives in an acceptable liquid.
The medicament containing the active ingredient acceptable for skin topical administration can be manufactured and distributed as ointments, oils, creams, lotions, gels, pastes and transdermal patch containing the active ingredient, other pharmaceutically active compounds, additives and an acceptable carrier medium. The medicament containing the active ingredient acceptable for nasal administration can be manufactured and distributed with other pharmaceutically active compounds and additives as a powder for inhalation, or as an oily, aqueous or non-aqueous liquid for nasal spray or drops.
The medicament containing the active ingredient acceptable for rectal administration can be manufactured and distributed as suppositories, creams, foams, douches or enemas with other pharmaceutically active compounds, suitable bases of the usual water-soluble diluents, fats, and additives known to practitioners of the art.
The medicament containing the active ingredient acceptable for vaginal administration can be manufactured and distributed as pessaries, suppositories, creams, gels, foams, douches or sprays with other pharmaceutically active compounds, suitable bases and additives known to practitioners of the art.
The medicament containing the active ingredient acceptable for parenteral administration can be manufactured and distributed from aqueous and non-aqueous sterile injection solutions, other pharmaceutically active compounds, additives including anti-oxidants, bacteriostats and solutes and sugars such as mannitol to make the medicament isotonic, hypotonic or hypertonic with the blood of the recipient; and also aqueous and non-aqueous sterile suspensions which can include suspenders and thickeners. The medicament can be manufactured and distributed in unit-dose or multi-dose containers, such as sealed glass or plastic ampoules, vials, bottles and bags as a liquid, and in a dry state requiring only the addition of sterile liquid, for example water, saline or dextrose solutions, immediately prior to use. Extemporaneous solutions and suspensions for injection can be prepared from powders and tablets of the kind above described. The medicament containing the active ingredient acceptable for administration into the brain and related structures, spinal cord and related structures, ventricular system and cerebrospinal fluid spaces can be manufactured and distributed from aqueous and non-aqueous sterile injection solutions, other pharmaceutically active compounds, additives including anti-oxidants, bacteriostats and solutes and sugars such as mannitol to make the medicament isotonic, hypotonic or hypertonic with the cerebrospinal fluid; and also aqueous and nonaqueous sterile suspensions which can include suspenders and thickeners. The medicament can be manufactured and distributed in unit-dose or multi-dose containers, such as sealed glass or plastic ampoules, vials, bottles and bags as a
liquid, and in a dry state requiring only the addition of sterile liquid, for example water, saline or dextrose solutions, immediately prior to use. Extemporaneous solutions and suspensions for injection can be prepared from powders and tablets of the kind above described. The desired unit dose of medicaments, are those containing a daily dose or immune insult treatment dose or an appropriate fraction thereof, of the administered active ingredient. Unit dose forms of the invention may also include more complex systems such as double barrelled syringes, syringes with sequential compartments one of which may contain the active ingredient, and the other any necessary diluents or vehicles. The agents in the syringes would be released sequentially or as a mixture or combination of the two after the triggering of the syringe plunger. Such systems are known in the art.
The medicament may be used for the treatment of a disease or disorder such as those mentioned above. Following examples are intended to illustrate, but not to limit, the invention in any manner, shape, or form, either explicitly or implicitly.
EXAMPLES
Example 1 : Organs prepared for transplantation was perfused with cold physiological salt saline (or sodium chloride) solution containing Zebularine at a concentration of 100 μM and incubated in that solution until the surgical transplantation procedure was performed. One day prior to transplantation, the recipient patient is treated with oral Zebularine at an optimal dose for induction of IDO at an immunosuppressive concentration and oral cyclosporine at standard dosage continued daily for 2 weeks and at a reduced dose level for another 2 weeks. During the 4 first days after surgery dexamethasone is administered intravenously at a daily dose of 8 mg and the dose is then tapered over the following 2 weeks. One month after transplantation cyclosporine treatment is stopped, whereas the Zebularine is continued and patients are closely watched for evidence of rejection. After 2 months of treatment with Zebularine alone this treatment is stopped provided nonresponsiveness to donor but not third part cells can be demonstrated in vitro.
Example 2: A patient with a bilateral severe ocular-surface disorder is to receive allogeneic corneal epithelial stem-cell transplantation (as reported by Tsubota et al, NEJM, 340,1697-1703, 1999). One day prior to transplantation the recipient patient is treated with oral Zebularine at an optimal dose for induction of IDO at an immunosuppressive concentration and oral cyclosporine at standard dosage
continued daily for 2 weeks and at a reduced dose level for another 2 weeks. During the 4 first days after surgery dexamethasone is administered intravenously at a daily dose of 8 mg and the dose is then tapered over the following 2 weeks. One month after transplantation cyclosporine treatment is stopped, whereas the Zebularine is continued and patients closely watched for evidence of rejection. After 2 months of treatment with Zebularine alone this treatment is stopped provided nonresponsiveness to donor but not third part cells can be demonstrated in vitro.
Example 3: A patient suffering from critical limb ischemia is subjected to gene therapy with direct intramuscular administration of the eukaryotic expression vector pUC18 encoding VEGF165 transcriptionally regulated by the cytomegalovirus promoter/enhancer in a total of 4 mg of DNA in 8 aliquots into the ischemic limb as previously described (Kalka et al., CIRC RES 2000; 86: 1198-1202). The day before gene transfer the patient receives oral Zebularine at an optimal dose for induction of IDO at an immunosuppressive concentration and this treatment is continued for 3 months by oral administration in order to prolong the action of the VEGF by protecting against the immune rejection of the muscle cells expressing the vector-encoded proteins. Plasma VEGF levels are measured by an ELISA assay to monitor the maintained expression of the transferred VEGF gene.
Example 4: A patient with active Rheumatoid Arthritis with considerable remaining symptoms despite treatment with Methotrexate 10 mg per week receives oral Zebularine at an optimal dose for induction of IDO at an immunosuppressive concentration. Methotrexate therapy is continued for 6 weeks. Zebularine therapy is then continued as single therapy for 3 months in order to induce immunosuppression and immunological tolerance.
Example 5: A patient with a diagnosis of relapsing-remitting multiple sclerosis, a score on the Expanded Disability Status Scale of 4 (on a range of 0-10), a MRI scan revealing lesions consistent with a diagnosis of multiple sclerosis, and having had a relapse despite having received treatment with interferon beta- Ia for more than 12 months at a dose of 30 microgram i.m. per week. At maintained interferon beta- Ia therapy oral Zebularine therapy is initiated at an optimal dose for induction of IDO at an immunosuppressive concentration. The interferon beta- Ia therapy is stopped after 3 weeks and Zebularine therapy continued for 12 months and then stopped provided that no relapse has occurred.
Example 6: A young patient with the diagnosis Diabetes Mellitus type I in an early stage is treated with insulin and within 3 weeks of diagnosis with oral Zebularine at
an optimal dose for induction of IDO at an immunosuppressive concentration. The required insulin dose is closely monitored beyond the expected initial decrease until it has stabilized at a low level or is no longer required. Zebularine therapy is maintained for 4 months and then stopped. Resumed Zebularine therapy dependent on a close monitoring of signs of increased requirement of insulin.
Example 7: Immune cells treated with zebularine in vitro (The use of in vitro treatment of immune cells with zebularine) can be utilized for transplantation. Peripheral blood from a patient with diabetes type I who is to receive a (that will be given) pancreatic beta cell transplant (transplantation) is collected. White blood cells from the patient blood are isolated and cultured in the presence of GMCSF, protein extract from the donor and zebularine. The cells are then stimulated with CpG-containing oligonucleotides and after further culture in vitro in presence of zebularine and HDAC inhibitors, regulatory plasmacytoid dendritic cells are enriched and are given back to the patient. (The in vitro treatment can also be combined with e.g., treatment with CTLA4-Ig or HDAC inhibitors.) These regulatory DC will then present antigens from the donor and induce tolerance against these foreign antigens. The beta cells from the donor are treated in vitro with zebularine prior to tranplantation. The patient can be given a pretreatment with zebularine, alone or in combination with HDAC-inhibitors, rapamycin, CTLA4-Ig, alone or in combination). The in vivo treatment will continue for about 2 weeks after transplantation of the pancreatic, insulin producing beta-cells. The patient is monitored by FACS analysis for presence of FoxP3 regulatory T-cells having T- cell receptors that can bind beta cell peptides conjugated with soluble fluorescent HLA-DR complexes. (The analysis is followed using a fluorescence activated cell sorter (FACS).) When an increased frequency (frequence) of regulatory T-cells can be identified, the immune suppressive treatment will be reduced until the patient does not need immune suppression and is cured.
Example 8: Immune cells treated with zebularine in vitro (The use of in vitro treatment of immune cells with zebularine) can be utilized in patients with autoimmune disease (for autoimmunity). Peripheral blood from a patient with reumatoid arthritis is collected. White blood cells from the patient blood are isolated and cultured in the presence of GMCSF, collagen or cartilage and zebularine. The cells are then stimulated with CpG-containing oligonucleotides and after further culture in vitro in presence of zebularine and HDAC inhibitors, regulatory plasmacytoid dendritic cells are enriched and are given back to the patient. (The in vitro treatment can also be combined with e.g., treatment with CTLA4-Ig or HDAC inhibitors.) These regulatory DC will then present antigens from collagen and
reinduce (induce) tolerance against these self antigens (that is broken) in the RA patient. The patient can be given a pretreatment with zebularine, alone or in combination with HDAC-inhibitors, rapamycin, CTLA4-Ig (alone or in combination). In vivo treatment will continue for about 2 weeks after injection of the in vitro treated tolerogenic DC cells. The patient is monitored by FACS analysis for presence of FoxP3 regulatory T-cells having T-cell receptors that can bind collagen peptides conjugated with soluble fluorescent HLA-DR complexes. The patient is also monitored for the presence of CD8+ effector T-cells with TcR that can bind soluble fluorescent HLA-A proteins conjugated with collagen peptides. (The analysis is followed using a fluorescence activated cell sorter (FACS).) When an increased frequency (frequence) of regulatory T-cells and a significant decrease in CD8+ effector cells can be identified, the immune suppressive treatment will be reduced until the patient does not need immune suppression and is cured, i.e., the natural tolerance has been restored.
Example 9: In an experiment the inventors tested the immunogenicity of genetically engineered rat colon cancer cells expressing rat interleukin 12. These cancer cells have repeteadly been used to immunize rats that create a strong immune response towards the rat tumour cells. The inventors pre-treated these rat colon cancer cells with 100 μM zebularine that rendered the rat colon cancer cells less immunogenic when used for immunization. This was congruent with the changes in expression of IDO (Fig. 3). Similar treatments of rat spleen cells and human buffy coat leukocytes induce enhanced IDO production and strong suppression of polyclonal lymphocyte proliferation, i.e. suppression of T cell activation. There is a very reproducible induction of IDO (about 20-fold) from different human leukocyte cultures with a slight interindividual variation. The suppression of proliferation can be blocked by addition of the IDO inhibitor 1 -methyl tryptophan (1-MT) as can be seen from figure 4.
References
Cheng, J.C. , C. B. Matsen, F.A. Gonzales, W. Ye5 S. Greer, V.E. Marquez, et al.5 Inhibition of DNA methylation and reactivation of silenced genes by Zebularineularine, Journal of the National Cancer Institute 95 (2003) 399-409.
Cheng, J.C. , D. J. Weisenberger, F.A. Gonzales, G. Liang, G. L. Xu, Y.G. Hu, et al., Continuous Zebularineularine treatment effectively sustains demethylation in human bladder cancer cells, Molecular and Cellular Biology 24 (2004) 1270- 1278.
Cheng, J.C, C. B. Yoo, D.J. Weisenberger, J. Chuang, C. Wozniak, G. Liang, et al., Preferential response of cancer cells to Zebularineularine, Cancer Cell 6 (2004) 151-158.
Liu, G. , H. Ying, G. Zeng, C. J. Wheeler, K. L. Black, J. S. Yu, HER-2, gplOO, and MAGE-I are expressed in human glioblastoma and recognized by cytotoxic T cells, Cancer Research, 64 (2004) 4980-4986.
Munn, D.H., M.D. Sharma, D. Hou, B. Baban, J.R.Lee, SJ. Antonia, et al., Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in draining-draining lymph nodes. The Journal of Clinical Investigation, 114 (2004) 280-290.
Obach R.S., Huynh P., Allen M.C., and Beedham C. Human Liver Aldehyde
Oxidase: Inhibition by 239 Drugs. Journal of Clinical Pharmacology, 2004; 44:7-19
Miki T, Sun H, Lee Y, Tandin A, Kovscek AM, Subbotin V, Fung JJ, Valdivia LA. Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts. 2001 Transplantation Proceedings, Volume 33, Issue 1-2, Pages 129- 130
Mellor, A.L., D.H. Munn, IDO expression by dendritic cells: tolerance and tryptophan catabolism, Nature Reviews Immunology 4 (2004) 762-774.
Uyttenhove, C. , L. Pilotte, I. Theate, V. Stroobant, D. Colau, N. Parmentier, et al., Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase, Nature Medicine 9 (2003) 1269-1274.
Claims
1. Use of 1 -(β-D-Ribofuranosyl)- 1 ,2-dihydropyrimidin-2-one, analogue, derivative or mimetic or salts thereof for the manufacturing of a medicament for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the treatment induces indolamine dioxygenase.
2. The use according to claim 1, wherein said analogue is selected from the group consisting of 5-methylcytidine, , 2'-deoxyzebularine, 5-fluoro- zebularine, 5-fluoro-2'-dexyzebularine, 5-chloro-zebularine, 5-chloro-2'- dexyzebularine, 5-bromo-zebularine, 5-bromo-2'-dexyzebularine, 5-iodo- zebularine, 5-iodo-2'-dexyzebularine, 5-methylpyrimidin-2-one, 5-Me-2'- deoxyzebularine, or mono, di or tri phosphates thereof.
3. The use according to any of claims 1-2, wherein said medicament comprises a pharmaceutically acceptable buffer, excipient, diluent or carrier .
4. The use according to any of preceding claims, wherein said medicament comprises at least two or more 1 -(β-D-Ribofuranosyl)- 1,2-dihydropyrimidin- 2-one, analogue, derivative or mimetic or salts thereof.
5. The use according to any of preceding claims, wherein said medicament comprises one or more additional active ingredient.
6. The use according to any of preceding claims, wherein said medicament further comprises at least one compound selected from the group consisting of metabolites of tryptophan, immuno suppressive agents, HDAC inhibitors and substances to increase bioavailability and/or to reduce degradation of 1- (β-D-Ribofuranosyl)- 1 ,2-dihydropyrimidin-2-one.
7. The use according to claim 6, wherein said compound is selected from the group consisting of aldehyde oxidase inhibitors selecetdf rom the group consisting of Raloxifene, Perphenazine, Thioridazine, Menadione, Trifluperazine, Amitriptyline, Estradiol, Felodipine, Clomipramine, Loratidine, Promethazine, Chlorpromazine, Ethinyl estradiol,
Norclomipramine, Amodiaquine, Nortriptylin to inhibit the oxidation of zebularine to uridine.
8. The use according to claim 6, wherein said compound is selected from the group consisting of Tryptophan, N-Formyl-kynurenine, Fonnylanthranilate, Anthranilate, L-Kynurenine, 4-(2-Aminophenyl)-2,4-dioxybutanoate,
Kynurenic acid, 3-Hydroxy-L-kynurenine, 3-Hydroxy-anthranilate, 3- Metoxy-anthranilate, 4-(2-Amino-3-hydroxy-phenyl)-2,4-dioxobutanoate, Xanthurenate, 8-Metoxy-kurenate, 2-Amino-3-carboxy-muconate semialdehyde, 2-Aminomuconate semialdehyde, Quimolinic acid, Cinnavalininate, Tryptamine, N-Methyltryptamine, Indoleacetate, 2- Formamino-benzoylacetate, 5-Hydroxy-L-tryptophan, 5-Hydroxy-N- foraiylkunerine, 5-Hydroxy-kunerine, 5-Hydroxy-kunerenamin, 4,6- Dihydroxy-quinoline, Serotonin, N-Acetyl-serotonin, Melatonin, 6-Hydroxy- melatonin, Formyl-N-acetyl-5-metoxykynurenamine, N-Methylserotonin,
Foπnyl-5-hydroxy-kynurenamine, 5-Metoxytryptamine, 5-Hydroxyindole- acetaldehyde, 5-Hydroxyindoleacetate, 5-Metoxyindoleacetate, or 5- Hydroxyindole-acetylglycine
9. The use according to claim 6, wherein said compound is selected from the group consisting of glycocorticoids, methotrexate, rapamycin, cyclophosphamide, antimetabolites including azathioprine, immunophilin- binding drugs (including tolerance, tacrolimus, sirolimus, everolimus), inhibitors of nucleotide synthesis (including mycophenolate mofetil, mizoribine, leflunomide, FK778), FTY720, lymphocyte depleting antibodies (including polyclonal antibodies to lymphocytes, thymocytes, T-cells, muromonab-CD3, rituximab, Alemtuzumab, CAMPATH-I), non-depleting antibodies (including daclizumab, basiliximab, the two CTLA-4-Ig fusion proteins LEA29Y and abatacept, LF A3 -Ig fusion protein), anti-TNF antibodies (including infliximab, adalimumab), natalizumab (anti-VLA-4), the anti-CD154 antibodies BG9588 and IDEC 131), soluble cytokine receptors (including lenercept and etanercept (soluble TNF p55 and TNF p75 receptors), histone deacetylase inhibitors and anakinra (soluble IL-IRA).
10. The use according to any of preceding claims, wherein said medicament is a tablet, a capsule, a solution or a powder.
11. The use according to any of preceding claims, wherein l-(β-D-
Ribofuranosyl)-l,2-dihydropyrimidin-2-one, analogue, derivative or mimetic or salts thereof is in an amount from about 5 to about 1000 uM.
12. The use according to any of preceding claims, wherein l-(β-D- Ribofuranosyl)-l,2-dihydropyrimidin-2-one, analogue, derivative or mimetic or salts thereof is in an amount of from about 50 to about 200 uM.
13. Use according to any of preceding claims, wherein said medicament is for the treatment of a disease selected from the group consisting of Achlorhydria, Acute hemorrhagic leukencephalitis, Addison's Disease, Alopecia Areata, Anemia, Pernicious Anti - Glomerular Basement Membrane Disease, Antiphospholipid Syndrome, Aplastic Anemia, Atopic
Allergy, Autoimmune Atrophic Gastritis, Autoimmune Hearing Loss, Autoimmune hemolytic anemia, Autoimmune hypoparathyroidism, Autoimmune hypophysitis, Autoimmune Lymphoproliferative, Autoimmune Myocarditis, Autoimmune oophoritis, Autoimmune orchitis, Autoimmune Polyendocrinopathy-Candidiasis-Ectodermal-Dystrophy, Autoimmune Syndrome Type II, Polyglandular, Behcet Syndrome, Celiac Disease, Chagas Disease, Cholangitis, Sclerosing, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic lymphocytic thyroiditis, Churg - Strauss Syndrome, Colitis, Ulcerative, Crohn's disease, Cryoglobulinemia, Gushing Syndrome,
Dermatitis Herpetiformis, Dermatomyositis, Diabetes Mellitus (Insulin - Dependent), Diffuse Cerebral Sclerosis of Schilder, Encephalomyelitis, Autoimmune, Experimental (EAE), Epidermolysis Bullosa Acquisita, Erythematosis, Felty's Syndrome, Glomerulonephritis (IGA), Glomerulonephritis Membranous, Goodpasture Syndrome, Graves' Disease,
Guillain - Barre Syndrome, Hamman-Rich syndrome, Hepatitis Autoimmune, Hepatitis Chronic Active, Idiopathic thrombocytopenia, Inflammatory Bowel Diseases, Insulin resistance - type B, Lambert - Eaton Myasthenic Syndrome, Lens-induced uveitis, Lichen Sclerosus et Atrophicus, Lupus Erythematosus Discoid, Lupus Erythematosus Systemic,
Lupus Hepatitis, Lupus Nephritis, Lymphopenia, Meniere's Disease, Mixed Connective Tissue Disease, Mooren's ulcer, Mucocutaneous Lymph Node Syndrome, Multiple Sclerosis, Myasthenia Gravis, Myelitis Transverse, Myocarditis, Narcolepsy, Neuritis Autoimmune Experimental, Neuromyelitis Optica, Oculovestibuloauditory syndrome, Ophthalmia Sympathetic,
Opsoclonus - Myoclonus Syndrome, Pancreatitis, Pemphigoid Bullous, Pemphigus foliaceous, Pemphigus Vulgaris, Polyarteritis Nodosa, Polychondritis Relapsing, Polyendocrinopathies Autoimmune, Polymyalgia Rheumatica, Polyradiculoneuropathy, Primary biliary cirrhosis, Psoriasis, Purpura Thrombocytopenic Idiopathic, Raynauds, Reiter Disease, Rheumatic
Fever, Rheumatoid Arthritis, Sarcoidosis, Scleroderma, Sjogren's Syndrome, Spondylitis Ankylosing, Stiff - Person Syndrome, Still's Disease Adult Onset, Takayasu's Arteritis, Temporal Arteritis, Thyrotoxicosis, Type B Insulin Resistance, Uveomeningoencephalitic Syndrome, Wegener's Granulomatosis, Vitiligo.
14. Use according to any of preceeding claims, wherein said medicament is for the treatment of Rheumatoid arthritis, Diabetes mellitus type I, Psoriasis, Sjogren's syndrome, Multiple Sclerosis, Crohn's disease, arteriosclerosis, Parkinson's disease, ALS (Amyotrophic lateral sclerosis) and dementia.
15. Use according to any of claims 1 - 12 , for the manufacturing of a medicament to be used in transplantations to inhibit immune rejection of organs, tissues, normal or genetherapeutically modified cells.
16. Compound ^(β-D-Ribofuranosy^-l^-dihydropyrimidin^-one, analogue, derivative or mimetic or salts thereof for the treatment of an autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the treatment induces indolamine dioxygenase.
17. The compound according to claim 16, wherein said analogue is selected from the group consisting of 5-methylcytidine, , 2'-deoxyzebularine, 5-fluoro- zebularine, 5-fluoro-2'-dexyzebularine, 5-chloro-zebularine, 5-chloro-2'- dexyzebularine, 5-bromo-zebularine, 5-bromo-2'-dexyzebularine, 5-iodo- zebularine, 5-iodo-2'-dexyzebularine, 5-methylpyrimidin-2-one, 5-Me-2'- deoxyzebularine, or mono, di or tri phosphates thereof.
18. The compound according to any of claims 16-17, wherein said compound is a medicament which comprises a pharmaceutically acceptable buffer, excipient, diluent or carrier .
19. The compound according to any of claims 16-18, wherein said medicament comprises at least two or more l-(β-D-Ribofuranosyl)-l,2-dihydropyrimidin- 2-one, analogue, derivative or mimetic or salts thereof.
20. The compound according to any of claims 16-19, wherein said medicament comprises one or more additional active ingredient.
21. The compound according to any of claims 16-20, wherein said medicament further comprises at least one additional compound selected from the group consisting of metabolites of tryptophan, irnmuno suppressive agents, HDAC inhibitors and substances to increase bioavailability and/or to reduce degradation of l-(β-D-Ribofuranosyl)-l,2-dihydropyrimidin-2-one.
22. The compound according to claim 21, wherein said additional compound is selected from the group consisting of aldehyde oxidase inhibitors selecetdf rom the group consisting of Raloxifene, Perphenazine, Thioridazine, Menadione, Trifluperazine, Amitriptyline, Estradiol, Felodipine,
Clomipramine, Loratidine, Promethazine, Chlorpromazine, Ethinyl estradiol, Norclomipramine, Amodiaquine, Nortriptylin to inhibit the oxidation of zebularine to uridine.
23. The compound according to claim 21, wherein said additional compound is selected from the group consisting of Tryptophan, N-Formyl-kynurenine,
Formylanthranilate, Anthranilate, L-Kynurenine, 4-(2-Aminophenyl)-2,4- dioxybutanoate, Kynurenic acid, 3-Hydroxy-L-kynurenine, 3-Hydroxy- anthranilate, 3-Metoxy-anthranilate, 4-(2-Amino-3-hydroxy-phenyl)-2,4- dioxobutanoate, Xanthurenate, 8-Metoxy-kurenate, 2-Amino-3-carboxy- muconate semialdehyde, 2-Aminomuconate semialdehyde, Quimolinic acid,
Cinnavalininate, Tryptamine, N-Methyltryptamine, Indoleacetate, 2- Formamino-benzoylacetate, 5-Hydroxy-L-tryptophan, 5-Hydroxy-N- formylkunerine, 5-Hydroxy-kunerine, 5-Hydroxy-kunerenamin, 4,6- Dihydroxy-quinoline, Serotonin, N-Acetyl-serotonin, Melatonin, 6-Hydroxy- melatonin, Foraiyl-N-acetyl-5-metoxykynurenamine, N-Methylserotonin, Foπnyl-5-hydroxy-kynurenamine, 5-Metoxytryptamine, 5-Hydroxyindole- acetaldehyde, 5-Hydroxyindoleacetate, 5-Metoxyindoleacetate, or 5- Hydroxyindole-acetylglycine
24. The compound according to claim 21, wherein said additional compound is selected from the group consisting of glycocorticoids, methotrexate, rapamycin, cyclophosphamide, antimetabolites including azathioprine, immunophilin-binding drugs (including tolerance, tacrolimus, sirolimus, everolimus), inhibitors of nucleotide synthesis (including mycophenolate mofetil, mizoribine, leflunomide, FK778), FTY720, lymphocyte depleting antibodies (including polyclonal antibodies to lymphocytes, thymocytes, T- cells, muromonab-CD3, rituximab, Alemtuzumab, CAMPATH-I), non- depleting antibodies (including daclizumab, basiliximab, the two CTLA-4-Ig fusion proteins LEA29Y and abatacept, LF A3 -Ig fusion protein), anti-TNF antibodies (including infliximab, adalimumab), natalizumab (anti-VLA-4), the anti-CD154 antibodies BG9588 and IDEC 131), soluble cytokine receptors (including lenercept and etanercept (soluble TNF p55 and TNF p75 receptors), histone deacetylase inhibitors and anakinra (soluble IL-IRA).
25. The compound according to claims 16-24, wherein said compound is a tablet, a capsule, a solution or a powder.
26. The compound according to any of claims 16-25, wherein l-(β-D- Ribofuranosyl)-l,2-dihydropyrimidin-2-one, analogue, derivative or mimetic or salts thereof is in an amount from about 5 to about 1000 uM.
27. The compound according to claim 26, wherein l-(β-D-Ribofuranosyl)-l,2- dihydropyrimidin-2-one, analogue, derivative or mimetic or salts thereof is in an amount of from about 50 to about 200 uM.
28. The compound according to any of claims 16-27, wherein said medicament is for the treatment of a disease selected from the group consisting of Achlorhydria, Acute hemorrhagic leukencephalitis, Addison's Disease, Alopecia Areata, Anemia, Pernicious Anti - Glomerular Basement
Membrane Disease, Antiphospholipid Syndrome, Aplastic Anemia, Atopic Allergy, Autoimmune Atrophic Gastritis, Autoimmune Hearing Loss, Autoimmune hemolytic anemia, Autoimmune hypoparathyroidism, Autoimmune hypophysitis, Autoimmune Lymphoproliferative, Autoimmune Myocarditis, Autoimmune oophoritis, Autoimmune orchitis, Autoimmune
Polyendocrinopathy-Candidiasis-Ectodermal-Dystrophy, Autoimmune Syndrome Type II, Polyglandular, Behcet Syndrome, Celiac Disease, Chagas Disease, Cholangitis, Sclerosing, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic lymphocytic thyroiditis, Churg - Strauss Syndrome, Colitis, Ulcerative, Crohn's disease, Cryoglobulinemia, Gushing Syndrome, Dermatitis Herpetiformis, Dermatomyositis, Diabetes Mellitus (Insulin - Dependent), Diffuse Cerebral Sclerosis of Schilder, Encephalomyelitis, Autoimmune, Experimental (EAE), Epidermolysis Bullosa Acquisita, Erythematosis, Felty's Syndrome, Glomerulonephritis (IGA),
Glomerulonephritis Membranous, Goodpasture Syndrome, Graves' Disease, Guillain - Barre Syndrome, Hamman-Rich syndrome, Hepatitis Autoimmune, Hepatitis Chronic Active, Idiopathic thrombocytopenia, Inflammatory Bowel Diseases, Insulin resistance - type B, Lambert - Eaton Myasthenic Syndrome, Lens-induced uveitis, Lichen Sclerosus et
Atrophicus, Lupus Erythematosus Discoid, Lupus Erythematosus Systemic, Lupus Hepatitis, Lupus Nephritis, Lymphopenia, Meniere's Disease, Mixed Connective Tissue Disease, Mooren's ulcer, Mucocutaneous Lymph Node Syndrome, Multiple Sclerosis, Myasthenia Gravis, Myelitis Transverse, Myocarditis, Narcolepsy, Neuritis Autoimmune Experimental, Neuromyelitis
Optica, Oculovestibuloauditory syndrome, Ophthalmia Sympathetic, Opsoclonus - Myoclonus Syndrome, Pancreatitis, Pemphigoid Bullous, Pemphigus foliaceous, Pemphigus Vulgaris, Polyarteritis Nodosa, Polychondritis Relapsing, Polyendocrinopathies Autoimmune, Polymyalgia Rheumatica, Polyradiculoneuropathy, Primary biliary cirrhosis, Psoriasis,
Purpura Thrombocytopenic Idiopathic, Raynauds, Reiter Disease, Rheumatic Fever, Rheumatoid Arthritis, Sarcoidosis, Scleroderma, Sjogren's Syndrome, Spondylitis Ankylosing, Stiff - Person Syndrome, Still's Disease Adult Onset, Takayasu's Arteritis, Temporal Arteritis, Thyrotoxicosis, Type B Insulin Resistance, Uveomeningoencephalitic Syndrome, Wegener's
Granulomatosis, and Vitiligo.
29. Use compound according to claim 28, wherein said medicament is for the treatment of Rheumatoid arthritis, Diabetes mellitus type I, Psoriasis, Sjδgrens syndrome, Multiple Sclerosis, Crohn's disease, arteriosclerosis, Parkinson's disease, ALS (Amyotrophic lateral sclerosis) and dementia.
30. The compound according to claims 16-27 to be used in transplantations to inhibit immune rejection of organs, tissues, normal or genetherapeutically modified cells.
31. A method of treating a mammal having a autoimmune disorder or disease or immune rejection of transplants or gene therapeutically modified cells, wherein the treatment induces indolamine dioxygenase, comprising administering to a patient a therapeutically effective amount of a medicament according to any of the claims 1-30.
32. The method according to claim 313 wherein said method comprises administering to a patient at least one compound selected from the group consisting of metabolites of tryptophan, immuno suppressive agents, HDAC inhibitors and substances to increase bioavailability and/or to reduce degradation of 1 -(β-D-Ribofuranosyl)- 1 ,2-dihydropyrimidin-2-one.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08753969.8A EP2164500B1 (en) | 2007-05-25 | 2008-05-26 | The use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants |
US12/601,021 US20110300142A1 (en) | 2007-05-25 | 2008-05-26 | Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants |
US14/940,657 US20160068809A1 (en) | 2007-05-25 | 2015-11-13 | Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0701275 | 2007-05-25 | ||
SE0701275-0 | 2007-05-25 | ||
US93347807P | 2007-06-07 | 2007-06-07 | |
US60/933,478 | 2007-06-07 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/601,021 A-371-Of-International US20110300142A1 (en) | 2007-05-25 | 2008-05-26 | Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants |
US14/940,657 Continuation US20160068809A1 (en) | 2007-05-25 | 2015-11-13 | Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008147283A1 true WO2008147283A1 (en) | 2008-12-04 |
Family
ID=40316847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2008/000352 WO2008147283A1 (en) | 2007-05-25 | 2008-05-26 | The use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants |
Country Status (3)
Country | Link |
---|---|
US (2) | US20110300142A1 (en) |
EP (1) | EP2164500B1 (en) |
WO (1) | WO2008147283A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012087234A1 (en) | 2010-12-22 | 2012-06-28 | Idogen Ab | A composition comprising at least to compounds which induces indolamine 2,3-dioxygenase (ido), for the treatment of an autoimmune disorder or suffering from immune rejection of organs |
EP2671574A1 (en) * | 2012-06-04 | 2013-12-11 | VitaK B.V. | Use of vitamin K to decrease allograft failure and patient mortality after organ transplantation |
WO2016146842A1 (en) * | 2015-03-19 | 2016-09-22 | Idogen Ab | Novel treatment method |
WO2018037103A1 (en) * | 2016-08-26 | 2018-03-01 | Idogen Ab | Procainamide for treating immune disorders and for modulating ido expression |
WO2018037105A1 (en) * | 2016-08-26 | 2018-03-01 | Idogen Ab | Psammaplin a for modulating ido expression |
WO2019081625A1 (en) | 2017-10-25 | 2019-05-02 | Allero Therapeutics Bvba | Treatment of immune diseases by administration of antigen-specific formulations |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
BR112022025381A2 (en) | 2020-06-11 | 2023-01-24 | Provention Bio Inc | METHODS AND COMPOSITIONS TO PREVENT TYPE 1 DIABETES |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003012051A2 (en) * | 2001-07-31 | 2003-02-13 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Inhibitor of dna methylation |
WO2003072757A2 (en) * | 2002-02-28 | 2003-09-04 | Biota, Inc. | Nucleotide mimics and their prodrugs |
WO2004037159A2 (en) * | 2002-10-23 | 2004-05-06 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
WO2004041195A2 (en) * | 2002-10-31 | 2004-05-21 | Supergen, Inc. | Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
WO2005009349A2 (en) * | 2003-07-22 | 2005-02-03 | Supergen, Inc. | Composition and method for treating neurological disorders |
WO2006116803A1 (en) * | 2005-04-29 | 2006-11-09 | Innovative Dairy Products Pty Ltd As Trustee For The Participants Of The Cooperative Research Centre For Innovative Dairy Products | A method for producing stem cells or stem cell-like cells from mammalian embryos |
WO2007016037A2 (en) * | 2005-07-27 | 2007-02-08 | Board Of Regents, The University Of Texas System | Methods for trans-differentiating cells |
US20070042976A1 (en) * | 2005-08-22 | 2007-02-22 | Gideon Strassmann | Method of treating cosmetic and dermatologic conditions by a demethylating agent |
WO2008028193A2 (en) * | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
-
2008
- 2008-05-26 EP EP08753969.8A patent/EP2164500B1/en not_active Not-in-force
- 2008-05-26 US US12/601,021 patent/US20110300142A1/en not_active Abandoned
- 2008-05-26 WO PCT/SE2008/000352 patent/WO2008147283A1/en active Application Filing
-
2015
- 2015-11-13 US US14/940,657 patent/US20160068809A1/en not_active Abandoned
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003012051A2 (en) * | 2001-07-31 | 2003-02-13 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon | Inhibitor of dna methylation |
WO2003072757A2 (en) * | 2002-02-28 | 2003-09-04 | Biota, Inc. | Nucleotide mimics and their prodrugs |
WO2004037159A2 (en) * | 2002-10-23 | 2004-05-06 | Obetherapy Biotechnology | Compounds, compositions and methods for modulating fat metabolism |
WO2004041195A2 (en) * | 2002-10-31 | 2004-05-21 | Supergen, Inc. | Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
WO2005009349A2 (en) * | 2003-07-22 | 2005-02-03 | Supergen, Inc. | Composition and method for treating neurological disorders |
WO2006116803A1 (en) * | 2005-04-29 | 2006-11-09 | Innovative Dairy Products Pty Ltd As Trustee For The Participants Of The Cooperative Research Centre For Innovative Dairy Products | A method for producing stem cells or stem cell-like cells from mammalian embryos |
WO2007016037A2 (en) * | 2005-07-27 | 2007-02-08 | Board Of Regents, The University Of Texas System | Methods for trans-differentiating cells |
US20070042976A1 (en) * | 2005-08-22 | 2007-02-22 | Gideon Strassmann | Method of treating cosmetic and dermatologic conditions by a demethylating agent |
WO2008028193A2 (en) * | 2006-09-01 | 2008-03-06 | Pharmion Corporation | Colon-targeted oral formulations of cytidine analogs |
Non-Patent Citations (1)
Title |
---|
See also references of EP2164500A4 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012087234A1 (en) | 2010-12-22 | 2012-06-28 | Idogen Ab | A composition comprising at least to compounds which induces indolamine 2,3-dioxygenase (ido), for the treatment of an autoimmune disorder or suffering from immune rejection of organs |
EP2654758A1 (en) * | 2010-12-22 | 2013-10-30 | Idogen AB | A composition comprising at least two compounds which induces indolamine 2,3-dioxygenase (ido), for the treatment of an autoimmune disorder or suffering from immune rejection of organs |
JP2014500312A (en) * | 2010-12-22 | 2014-01-09 | イドゲン アクチエボラグ | Composition comprising at least two compounds inducing indoleamine-2,3-dioxygenase (IDO) for treating pain due to autoimmune disorders or organ immune rejection |
EP2654758A4 (en) * | 2010-12-22 | 2014-05-07 | Idogen Ab | A composition comprising at least two compounds which induces indolamine 2,3-dioxygenase (ido), for the treatment of an autoimmune disorder or suffering from immune rejection of organs |
US9839674B2 (en) | 2010-12-22 | 2017-12-12 | Idogen Ab | Methods of inducing indolamine 2,3—dioxygenase (IDO) |
EP3238726A3 (en) * | 2010-12-22 | 2018-01-10 | Idogen AB | Composition comprising interferon gamma and an hdac inhibitor or gonadotropin receptor signalling hormone |
EP2671574A1 (en) * | 2012-06-04 | 2013-12-11 | VitaK B.V. | Use of vitamin K to decrease allograft failure and patient mortality after organ transplantation |
WO2013182578A1 (en) | 2012-06-04 | 2013-12-12 | Vitak B.V. | Use of vitamin k to decrease allograft failure and patient mortality after organ transplantation |
WO2016146842A1 (en) * | 2015-03-19 | 2016-09-22 | Idogen Ab | Novel treatment method |
WO2018037103A1 (en) * | 2016-08-26 | 2018-03-01 | Idogen Ab | Procainamide for treating immune disorders and for modulating ido expression |
WO2018037105A1 (en) * | 2016-08-26 | 2018-03-01 | Idogen Ab | Psammaplin a for modulating ido expression |
WO2019081625A1 (en) | 2017-10-25 | 2019-05-02 | Allero Therapeutics Bvba | Treatment of immune diseases by administration of antigen-specific formulations |
Also Published As
Publication number | Publication date |
---|---|
US20160068809A1 (en) | 2016-03-10 |
EP2164500B1 (en) | 2013-12-04 |
US20110300142A1 (en) | 2011-12-08 |
EP2164500A4 (en) | 2012-07-11 |
EP2164500A1 (en) | 2010-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20160068809A1 (en) | Use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants | |
US20180028621A1 (en) | Methods of inducing indolamine 2,3 - dioxygenase (ido) | |
US20230081530A1 (en) | Methods and compositions for treating cancer using mrna therapeutics | |
Ye et al. | Hydroxysafflor yellow A protects neuron against hypoxia injury and suppresses inflammatory responses following focal ischemia reperfusion in rats | |
JP5643237B2 (en) | Method for inhibiting apoptosis of photoreceptor cells | |
Li et al. | The role of Wnt/β-catenin pathway in the protection process by dexmedetomidine against cerebral ischemia/reperfusion injury in rats | |
JP7089603B2 (en) | Demethylation to treat eye diseases | |
US10350231B2 (en) | Use of cladribine for treating autoimmune inflammatory disease | |
EP2744502B1 (en) | Methods useful in the prevention of hypoxic injury | |
JP2004517818A (en) | Cell damage inhibitor | |
WO1995005834A1 (en) | Use of 2-deoxycoformycin (pentostatin) for treating cerebral and cardiovascular disorders | |
Cao et al. | Attenuation of Microglial Activation and Pyroptosis by Inhibition of P2X7 Pathway Promotes Photoreceptor Survival in Experimental Retinal Detachment | |
JP2008530008A (en) | Method for predicting and preventing oxygen-induced inflammatory tissue injury | |
US20230277650A1 (en) | Use of a birnavirus for the treatment of a disease caused by varicella zoster virus (vzv) | |
US20230338356A1 (en) | Treatment of autoimmune skin disease | |
WO2024029597A1 (en) | DRY EYE REMEDY CONTAINING DNA OLIGONUCLEOTIDE SELECTIVELY BINDING TO IFN-γ | |
RU2812805C1 (en) | Method of inhibiting pd-1/pd-l1 signaling pathway in bladder cancer cells | |
AU2019101780A4 (en) | Use of SPHK2 inhibitor as drug for repairing bone marrow hematopoietic system injury or treating bone marrow hematopoietic dysfunction | |
US7329643B2 (en) | Inhibition of HMGB1 release by fetuin | |
RU2245137C1 (en) | Pharmaceutical composition for threatment of viral inflammations in eyeball | |
Schwartz et al. | Therapeutic T-cell-based vaccination versus pharmacological intervention for neuroprotection: restoring lost homeostasis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08753969 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008753969 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12601021 Country of ref document: US |